2010

Diem-Zangerl A, Seppi K, Oberaigner W, Poewe W. Mortality in Parkinson's disease, a 20-year follow-up study. Mov Disord 2010; 25: 661-2.

Grabner G, Haubenberger D, Rath J, Beisteiner R, Auff E, Trattnig S, Barth M. A population-specific symmetric phase model to automatically analyze susceptibility-weighted imaging (SWI) phase shifts and phase symmetry in the human brain. J Magn Reson Imaging. 2010 Jan;31(1):215-20.

Houlden H, Schneider SA, Paudel R, Melchers A, Schwingenschuh P, Edwards M, Hardy J, Bhatia KP. THAP1 mutations (DYT6) are an additional cause of early-onset dystonia. Neurology. 2010 Mar 9;74(10):846-50.

Katschnig P, Edwards MJ, Schwingenschuh P, Aguirregomozcorta M, Kägi G, Rothwell JC, Bhatia KP. Mental rotation of body parts and sensory temporal discrimination in fixed dystonia. Mov Disord. 2010 Mar 22. [Epub ahead of print]

Moore JW, Schneider SA, Schwingenschuh P, Moretto G, Bhatia KP, Haggard P. Dopaminergic medication boosts action-effect binding in Parkinson's disease. Neuropsychologia. 2010 Mar;48(4):1125-32.

Schwingenschuh P, Ruge D, Edwards MJ, Terranova C, Katschnig P, Carrillo F, Silveira-Moriyama L, Schneider SA, Kägi G, Palomar FJ, Talelli P, Dickson J, Lees AJ, Quinn N, Mir P, Rothwell JC, Bhatia KP. Distinguishing SWEDDs patients with asymmetric resting tremor from Parkinson's disease: a clinical and electrophysiological study. Mov Disord. 2010 Apr 15;25(5):560-9.

Seppi K, Poewe W. Brain magnetic resonance imaging techniques in the diagnosis of parkinsonian syndromes. Neuroimaging Clin N Am 2010; 20: 29-55.

Stemberger S, Poewe W, Wenning GK, Stefanova N. Targeted overexpression of human alpha-synuclein in oligodendroglia induces lesions linked to MSA -like progressive autonomic failure. Exp Neurol 2010.

Schwingenschuh P, Katschnig P, Saurugg R, Ott E, Bhatia KP. Artistic profession: a potential risk factor for dopamine dysregulation syndrome in Parkinson's disease? Mov Disord. 2010 Mar 15;25(4):493-6.

Winter Y, von Campenhausen S, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Botzel K, Oertel WH, Dodel R, Poewe W. Social and clinical determinants of quality of life in Parkinson's disease in Austria: a cohort study. J Neurol 2010; 257: 638-45.

Wolf E, Seppi K, Katzenschlager R, Hochschorner G, Ransmayr G, Schwingenschuh P, Ott E, Kloiber I, Haubenberger D, Auff E, Poewe W. Long-term antidyskinetic efficacy of amantadine in Parkinson's disease. Mov Disord. 2010 Mar 2. [Epub ahead of print]

2009

Antonini A, Tolosa E, Mizuno Y, Yamamoto M, Poewe WH. A reassessment of risks and benefits of dopamine agonists in Parkinson's disease. Lancet Neurol 2009; 8: 929-37.

Delazer M, Sinz H, Zamarian L, Stockner H, Seppi K, Wenning GK, Benke T, Poewe W. Decision making under risk and under ambiguity in Parkinson's disease. Neuropsychologia 2009; 47: 1901-8.

Diem-Zangerl A, Seppi K, Wenning GK, Trinka E, Ransmayr G, Oberaigner W, Poewe W. Mortality in Parkinson's disease: a 20-year follow-up study. Mov Disord 2009; 24: 819-25.

Haubenberger D, Hotzy C, Pirker W, Katzenschlager R, Brücke T, Zimprich F, Auff E, Zimprich A. Role of LINGO1 polymorphisms in Parkinson's disease. Mov Disord. 2009 Dec 15;24(16):2404-7.

Haubenberger D, Reinthaler E, Mueller JC, Pirker W, Katzenschlager R, Froehlich R, Bruecke T, Daniel G, Auff E, Zimprich A. Association of transcription factor polymorphisms PITX3 and EN1 with Parkinson's disease. Neurobiol Aging. 2009 Apr 2. [Epub ahead of print]

Kemlink D, Polo O, Frauscher B, Gschliesser V, Högl B, Poewe W, Vodicka P, Vavrova J, Sonka K, Nevsimalova S, Schormair B, Lichtner P, Silander K, Peltonen L, Gieger C, Wichmann HE, Zimprich A, Roeske D, Müller-Myhsok B, Meitinger T, Winkelmann J. Replication of restless legs syndrome loci in three European populations. J Med Genet. 2009 May;46(5):315-8. Epub 2009 Mar 10.

Kollensperger M, Stefanova N, Pallua A, Puschban Z, Dechant G, Hainzer M, Reindl M, Poewe W, Nikkhah G, Wenning GK. Striatal transplantation in a rodent model of multiple system atrophy: effects on L-Dopa response. J Neurosci Res 2009; 87: 1679-85.

Kranz G, Haubenberger D, Voller B, Posch M, Schnider P, Auff E, Sycha T. Respective potencies of Botox and Dysport in a human skin model: a randomized, double-blind study. Mov Disord. 2009 Jan 30;24(2):231-6.

Kranz G, Shamim EA, Lin PT, Kranz GS, Voller B, Hallett M. Blepharospasm and the modulation of cortical excitability in primary and secondary motor areas. Neurology. 2009 Dec 8;73(23):2031-6.

Peralta CM, Frauscher B, Seppi K, Wolf E, Wenning GK, Hogl B, Poewe W. Restless legs syndrome in Parkinson's disease. Mov Disord 2009; 24: 2076-80.

Pirio Richardson S, Bliem B, Voller B, Dang N, Hallett M. Long-latency afferent inhibition during phasic finger movement in focal hand dystonia. Exp Brain Res. 2009 Feb;193(2):173-9. Epub 2008 Oct 21.

Pusswald G, Fleck M, Haubenberger D, Auff E, Weber G. [What roll does the sense of coherence in coping with Morbus Parkinson play?] Z Gerontol Geriatr. 2009 Jun;42(3):220-7. Epub 2009 Jun 28. German.

Schapira AH, Emre M, Jenner P, Poewe W. Levodopa in the treatment of Parkinson's disease. Eur J Neurol 2009; 16: 982-9.

Schwingenschuh P, Cordivari C, Czerny J, Esposito M, Bhatia KP. Tremor on smiling. Mov Disord. 2009 Jul 30;24(10):1542-5.

Poewe W. Clinical measures of progression in Parkinson's disease. Mov Disord 2009; 24 Suppl 2: S671-6.

Poewe W. Treatments for Parkinson disease--past achievements and current clinical needs. Neurology 2009; 72: S65-73.

Poewe W, Auff E, Fazekas F. Neurological letter from Austria. Pract Neurol 2009; 9: 298-301.

Poewe W, Mahlknecht P. The clinical progression of Parkinson's disease. Parkinsonism Relat Disord 2009; 15 Suppl 4: S28-32.

Poewe W, Scherfler C, Tolosa E, Marek K. Supplement neuroimaging movement disorders. Mov Disord 2009; 24 Suppl 2: S655.

Silveira-Moriyama L, Schwingenschuh P, O'Donnell A, Schneider SA, Mir P, Carrillo F, Terranova C, Petrie A, Grosset DG, Quinn NP, Bhatia KP, Lees AJ. Olfaction in patients with suspected parkinsonism and scans without evidence of dopaminergic deficit (SWEDDs). J Neurol Neurosurg Psychiatry. 2009 Jul;80(7):744-8.

Stefansson H, Steinberg S, Petursson H, Gustafsson O, Gudjonsdottir IH, Jonsdottir GA, Palsson ST, Jonsson T, Saemundsdottir J, Bjornsdottir G, Böttcher Y, Thorlacius T, Haubenberger D, Zimprich A, Auff E, Hotzy C, Testa CM, Miyatake LA, Rosen AR, Kristleifsson K, Rye D, Asmus F, Schöls L, Dichgans M, Jakobsson F, Benedikz J, Thorsteinsdottir U, Gulcher J, Kong A, Stefansson K. Variant in the sequence of the LINGO1 gene confers risk of essential tremor. Nat Genet. 2009 Mar;41(3):277-9. Epub 2009 Feb 1. Erratum in: Nat Genet. 2009 Apr;41(4):504.

Stefanova N, Hainzer M, Stemberger S, Couillard-Despres S, Aigner L, Poewe W, Wenning GK. Striatal transplantation for multiple system atrophy--are grafts affected by alpha-synucleinopathy? Exp Neurol 2009; 219: 368-71.

Svehlík M, Zwick EB, Steinwender G, Linhart WE, Schwingenschuh P, Katschnig P, Ott E, Enzinger C. Gait analysis in patients with Parkinson's disease off dopaminergic therapy. Arch Phys Med Rehabil. 2009 Nov;90(11):1880-6.

Tolosa E, Poewe W. Premotor Parkinson disease. Neurology 2009; 72: S1.

Trender-Gerhard I, Sweeney MG, Schwingenschuh P, Mir P, Edwards MJ, Gerhard A, Polke JM, Hanna MG, Davis MB, Wood NW, Bhatia KP. Autosomal-dominant GTPCH1-deficient DRD: clinical characteristics and long-term outcome of 34 patients. J Neurol Neurosurg Psychiatry. 2009 Aug;80(8):839-45.

von Campenhausen S, Winter Y, Gasser J, Seppi K, Reese JP, Pfeiffer KP, Geiger-Gritsch S, Botzel K, Siebert U, Oertel WH, Dodel R, Poewe W. [Cost of illness and health service patterns in Morbus Parkinson in Austria]. Wien Klin Wochenschr 2009; 121: 574-82.

Wohlfarth K, Sycha T, Ranoux D, Naver H, Caird D. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin. 2009 Jul;25(7):1573-84. Review.

Zimprich A, Schulte C, Reinthaler E, Haubenberger D, Balzar J, Lichtner P, El Tawil S, Edris S, Foki T, Pirker W, Katzenschlager R, Daniel G, Brücke T, Auff E, Gasser T. PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. Parkinsonism Relat Disord. 2009 Aug;15(7):532-4. Epub 2009 Feb 27.

2008

Kägi G, Schwingenschuh P, Bhatia KP. Arm swing is reduced in idiopathic cervical dystonia. Mov Disord. 2008 Sep 15;23(12):1784-7.

Kollensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J, Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke N, Dodel R, Oertel W, Dupont E, Ostergaard K, Daniels C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, Sorbo FD, Albanese A, Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C, Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A, Poewe W, Wenning GK. Red flags for multiple system atrophy. Mov Disord 2008; 23: 1093-9.

Kranz G, Sycha T, Voller B, Kranz GS, Schnider P, Auff E. Neutralizing antibodies in dystonic patients who still respond well to botulinum toxin type A. Neurology. 2008 Jan 8;70(2):133-6.

Paus S, Grünewald A, Klein C, Knapp M, Zimprich A, Janetzky B, Möller JC, Klockgether T, Wüllner U. The DRD2 TaqIA polymorphism and demand of dopaminergic medication in Parkinson's disease. Mov Disord. 2008 Mar 15;23(4):599-602.

Ransmayr GN, Holliger S, Schletterer K, Heidler H, Deibl M, Poewe W, Madersbacher H, Kiss G. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008 Jan 22;70(4):299-303.

Schormair B, Kemlink D, Roeske D, Eckstein G, Xiong L, Lichtner P, Ripke S, Trenkwalder C, Zimprich A, Stiasny-Kolster K, Oertel W, Bachmann CG, Paulus W, Högl B, Frauscher B, Gschliesser V, Poewe W, Peglau I, Vodicka P, Vávrová J, Sonka K, Nevsimalova S, Montplaisir J, Turecki G, Rouleau G, Gieger C, Illig T, Wichmann HE, Holsboer F, Müller-Myhsok B, Meitinger T, Winkelmann J. PTPRD (protein tyrosine phosphatase receptor type delta) is associated with restless legs syndrome. Nat Genet. 2008 Aug;40(8):946-8. Epub 2008 Jul 27.

Schwingenschuh P, Bhatia KP. Painful moving tongue in a patient with the painful legs moving toes syndrome. Mov Disord. 2008 Jul 15; 23(9):1324-5.

Schwingenschuh P, Pont-Sunyer C, Surtees R, Edwards MJ, Bhatia KP. Psychogenic movement disorders in children: a report of 15 cases and a review of the literature. Mov Disord. 2008 Oct 15;23(13):1882-8. Review.

Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 2008; 210: 421-7.

Trenkwalder C, Boesch S, Ceballos-Baumann A, Dressler D, Eggert K, Gasser T, Honig H, Muller T, Reichmann H, Sieb JP, Storch A, Odin P, Poewe W. [Intermittent apomorphine injections as rescue therapy for advanced Parkinson's disease. Consensus statement]. Nervenarzt 2008; 79: 475-9.

Wenning GK, Stefanova N, Jellinger KA, Poewe W, Schlossmacher MG. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 2008; 64: 239-46.

Zimprich A, Hatala K, Riederer F, Stogmann E, Aschauer HN, Stamenkovic M. Sequence analysis of the complete SLITRK1 gene in Austrian patients with Tourette's disorder. Psychiatr Genet. 2008 Dec;18(6):308-9.

2007

Aarsland D, Emre M, Lees A, Poewe W, Ballard C. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. Jan 2 2007;68(1):80; author reply 81.

Antonini A, Poewe W. Fibrotic heart-valve reactions to dopamine-agonist treatment in Parkinson's disease. Lancet Neurol. Sep 2007;6(9):826-829.

Asmus F, Devlin A, Munz M, Zimprich A, Gasser T, Chinnery PF. Clinical differentiation of genetically proven benign hereditary chorea and myoclonus-dystonia. Mov Disord. 2007 Oct 31;22(14):2104-9.Bouzgarou E, Dupeyron A, Castelnovo G, et al. [Camptocormia disclosing Parkinson's disease]. Ann Readapt Med Phys. Jan 2007;50(1):55-59.  

Brenneis C, Egger K, Scherfler C, et al. Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J Neurol. Feb 2007;254(2):191-196.

Chaudhuri KR, Martinez-Martin P, Brown RG, et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord. Aug 2 2007.

Ciucci MR, Ma ST, Fox C, Kane JR, Ramig LO, Schallert T. Qualitative changes in ultrasonic vocalization in rats after unilateral dopamine depletion or haloperidol: a preliminary study. Behav Brain Res. Sep 4 2007;182(2):284-289.

Frauscher B, Gschliesser V, Brandauer E, et al. Video analysis of motor events in REM sleep behavior disorder. Mov Disord. Jul 30 2007;22(10):1464-1470.

Goetz CG, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Process, format, and clinimetric testing plan. Mov Disord. Jan 2007;22(1):41-47.

Grunblatt E, Salkovic-Petrisic M, Osmanovic J, Riederer P, Hoyer S. Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein. J Neurochem. May 2007;101(3):757-770.

Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H. Olfactory loss may be a first sign of idiopathic Parkinson's disease. Mov Disord. Apr 30 2007;22(6):839-842.

Haubenberger D, Bonelli S, Hotzy C, Leitner P, Lichtner P, Samal D, Katzenschlager R, Djamshidian A, Brücke T, Steffelbauer M, Bancher C, Grossmann J, Ransmayr G, Strom TM, Meitinger T, Gasser T, Auff E, Zimprich A. A novel LRRK2 mutation in an Austrian cohort of patients with Parkinson's disease. Mov Disord. 2007 Aug 15;22(11):1640-3.

Huang C, Tang C, Feigin A, et al. Changes in network activity with the progression of Parkinson's disease. Brain. Jul 2007;130(Pt 7):1834-1846.

Hunsche S, Sauner D, Maarouf M, Lackner K, Sturm V, Treuer H. Combined x-ray and magnetic resonance imaging facility: application to image-guided stereotactic and functional neurosurgery. Neurosurgery. Apr 2007;60(4 Suppl 2):352-360; discussion 360-351.

Jacob CP, Koutsilieri E, Bartl J, et al. Alterations in expression of glutamatergic transporters and receptors in sporadic Alzheimer's disease. J Alzheimers Dis. Mar 2007;11(1):97-116.

Jellinger KA. 5th International Congress on the Improvement of the Quality of Life on Dementia, Parkinson's disease, Epilepsy, Multiple Sclerosis and Muscular Disorders. Expert Rev Neurother. Mar 2007;7(3):241-243.

Junghanns S, Fuhrmann JT, Simonis G, et al. Valvular heart disease in Parkinson's disease patients treated with dopamine agonists: a reader-blinded monocenter echocardiography study. Mov Disord. Jan 15 2007;22(2):234-238.

Katzenschlager R, Schrag A, Evans A, et al. Quantifying the impact of dyskinesias in PD: the PDYS-26: a patient-based outcome measure. Neurology. Aug 7 2007;69(6):555-563.

Kollensperger M, Seppi K, Liener C, et al. Diffusion weighted imaging best discriminates PD from MSA-P: A comparison with tilt table testing and heart MIBG scintigraphy. Mov Disord. Jun 19 2007.

Kollensperger M, Stefanova N, Reindl M, Poewe W, Wenning GK. Loss of dopaminergic responsiveness in a double lesion rat model of the Parkinson variant of multiple system atrophy. Mov Disord. Feb 15 2007;22(3):353-358.

Korczyn AD, Reichmann H, Boroojerdi B, Hack HJ. Rotigotine transdermal system for perioperative administration. J Neural Transm. Feb 2007;114(2):219-221.

Loscher WN, Stampfer-Kountchev M, Sawires M, et al. Abnormal responses to repetitive transcranial magnetic stimulation in multiple system atrophy. Mov Disord. Jan 15 2007;22(2):174-178.

Martinez-Rodriguez JE, Seppi K, Cardozo A, et al. Cerebrospinal fluid hypocretin-1 levels in multiple system atrophy. Mov Disord. Jul 20 2007.

Mortiboys HJ, Schaefer J, Reichmann H, Jackson S. Mitochondrial dysfunction in Parkinson's disease--revisited. Neurol Neurochir Pol. Mar-Apr 2007;41(2):150-159.

Mossner R, Riederer P. Allelic variation of a functional promoter polymorphism of the serotonin transporter and depression in Parkinson's disease. Parkinsonism Relat Disord. Feb 2007;13(1):62.

Poewe WH, Rascol O, Quinn N, et al. Efficacy of pramipexole and transdermal rotigotine in advanced Parkinson's disease: a double-blind, double-dummy, randomised controlled trial. Lancet Neurol. Jun 2007;6(6):513-520.

Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord. Feb 15 2007;22(3):313-318.

Ransmayr G. Constantin von Economo's contribution to the understanding of movement disorders. Mov Disord. 2007 Mar 15;22(4):469-75.  

Ransmayr G, Katzenschlager R, Dal-Bianco P, et al. [Dementia with Lewy Bodies and its differentiation from Alzheimer's disease]. Neuropsychiatr. 2007;21(2):63-74.

Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. Jun 15 2007;22(8):1077-1092.

Schwingenschuh P, Wenzel K, Katschnig P, Saurugg R, Ott E. Case of a palatal tic resembling palatal tremor in a patient with Tourette syndrome. Mov Disord. 2007 Apr 15;22(5):742-5.

Seppi K, Rascol O. Dementia with Lewy bodies and Parkinson disease with dementia: can MRI make the difference? Neurology. Aug 21 2007;69(8):717-718.

Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J Neurosurg. Apr 2007;106(4):614-620.

Stockner H, Sojer M, K KS, et al. Midbrain sonography in patients with essential tremor. Mov Disord. Feb 15 2007;22(3):414-417.

Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q(10) in Parkinson disease. Arch Neurol. Jul 2007;64(7):938-944.

Ulmanová O, Homann CN, Ulman R, Jech R, Capek V, Klempír J, Růzicka E. Tremor magnitude: a single index to assess writing and drawing in essential tremor. Parkinsonism Relat Disord. 2007 May;13(4):250-3.

Winkelmann J, Schormair B, Lichtner P, Ripke S, Xiong L, Jalilzadeh S, Fulda S, Pütz B, Eckstein G, Hauk S, Trenkwalder C, Zimprich A, Stiasny-Kolster K, Oertel W, Bachmann CG, Paulus W, Peglau I, Eisensehr I, Montplaisir J, Turecki G, Rouleau G, Gieger C, Illig T, Wichmann HE, Holsboer F, Müller-Myhsok B, Meitinger T. Genome-wide association study of restless legs syndrome identifies common variants in three genomic regions. Nat Genet. 2007 Aug;39(8):1000-6. Epub 2007 Jul 18. 

2006

Wang F, Chen B, Feng XL, et al. [PINK1 IVS5-5 G>A polymorphism may contribute to the risk of late onset Parkinson disease in Chinese]. Zhonghua Yi Xue Yi Chuan Xue Za Zhi. Jun 2007;24(3):305-309.

Asanuma K, Tang C, Ma Y, et al. Network modulation in the treatment of Parkinson's disease. Brain. Oct 2006;129(Pt 10):2667-2678.

Ba M, Kong M, Yang H, et al. Changes in subcellular distribution and phosphorylation of GluR1 in lesioned striatum of 6-hydroxydopamine-lesioned and l-dopa-treated rats. Neurochem Res. Nov 2006;31(11):1337-1347.
 
Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord. Jul 2006;21(7):916-923. 

Clarimon J, Scholz S, Fung HC, et al. Conflicting results regarding the semaphorin gene (SEMA5A) and the risk for Parkinson disease. Am J Hum Genet. Jun 2006;78(6):1082-1084; author reply 1092-1084.

Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep-brain stimulation for Parkinson's disease. N Engl J Med. Aug 31 2006;355(9):896-908.

Ebersbach G, Poewe W. [Vascular parkinsonian syndrome]. Nervenarzt. Feb 2006;77(2):139-144, 146-137.

Eblan MJ, Scholz S, Stubblefield B, et al. Glucocerebrosidase mutations are not found in association with LRRK2 G2019S in subjects with parkinsonism. Neurosci Lett. Aug 14 2006;404(1-2):163-165.

Evans AH, Lawrence AD, Potts J, et al. Relationship between impulsive sensation seeking traits, smoking, alcohol and caffeine intake, and Parkinson's disease. J Neurol Neurosurg Psychiatry. Mar 2006;77(3):317-321.

Fung HC, Scholz S, Matarin M, et al. Genome-wide genotyping in Parkinson's disease and neurologically normal controls: first stage analysis and public release of data. Lancet Neurol. Nov 2006;5(11):911-916.

Gerlach M, Double KL, Youdim MB, Riederer P. Potential sources of increased iron in the substantia nigra of parkinsonian patients. J Neural Transm Suppl. 2006(70):133-142.

Gossrau G, Herting B, Mockel S, et al. Analysis of the polymorphic prion protein gene codon 129 in idiopathic Parkinson's disease. J Neural Transm. Mar 2006;113(3):331-337.

Grunblatt E, Koutsilieri E, Hoyer S, Riederer P. Gene expression alterations in brain areas of intracerebroventricular streptozotocin treated rat. J Alzheimers Dis. Aug 2006;9(3):261-271.

Hauser RA, Russ H, Haeger DA, Bruguiere-Fontenille M, Muller T, Wenning GK. Patient evaluation of a home diary to assess duration and severity of dyskinesia in Parkinson disease. Clin Neuropharmacol. Nov-Dec 2006;29(6):322-330.

Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies and the Movement Disorder Society-European Section. Part I: early (uncomplicated) Parkinson's disease. Eur J Neurol. Nov 2006;13(11):1170-1185.

Horstink M, Tolosa E, Bonuccelli U, et al. Review of the therapeutic management of Parkinson's disease. Report of a joint task force of the European Federation of Neurological Societies (EFNS) and the Movement Disorder Society-European Section (MDS-ES). Part II: late (complicated) Parkinson's disease. Eur J Neurol. Nov 2006;13(11):1186-1202.

Hu MT, Scherfler C, Khan NL, et al. Nigral degeneration and striatal dopaminergic dysfunction in idiopathic and Parkin-linked Parkinson's disease. Mov Disord. Mar 2006;21(3):299-305.

Inzelberg R, Bonuccelli U, Schechtman E, et al. Association between amantadine and the onset of dementia in Parkinson's disease. Mov Disord. Sep 2006;21(9):1375-1379.

Jellinger K. [The vascular Parkinson syndrome]. Nervenarzt. Jun 2006;77(6):729-730.

Jellinger K. A response to The effects of vascular disease on late onset Parkinson's disease (Papapetropoulos et al.). Eur J Neurol. Oct 2006;13(10):e1; author reply e2.

Jellinger KA. Pathological substrate of dementia in Parkinson's disease--its relation to DLB and DLBD. Parkinsonism Relat Disord. Mar 2006;12(2):119-120.

Jellinger KA. Neuropathology of dementia in Parkinson's disease. Ann Neurol. Apr 2006;59(4):727.

Jellinger KA. P25alpha immunoreactivity in multiple system atrophy and Parkinson disease. Acta Neuropathol (Berl). Jul 2006;112(1):112.

Jellinger KA. The morphological basis of mental dysfunction in Parkinson's disease. J Neurol Sci. Oct 25 2006;248(1-2):167-172.

Jellinger KA. Clinicopathological analysis of dementia disorders in the elderly--an update. J Alzheimers Dis. 2006;9(3 Suppl):61-70.

Jellinger KA, Attems J. Prevalence and impact of cerebrovascular pathology in Alzheimer's disease and parkinsonism. Acta Neurol Scand. Jul 2006;114(1):38-46.

Jellinger KA, Attems J. Does striatal pathology distinguish Parkinson disease with dementia and dementia with Lewy bodies? Acta Neuropathol (Berl). Sep 2006;112(3):253-260.

Kalteis K, Standhardt H, Kryspin-Exner I, Brucke T, Volc D, Alesch F. Influence of bilateral Stn-stimulation on psychiatric symptoms and psychosocial functioning in patients with Parkinson's disease. J Neural Transm. Sep 2006;113(9):1191-1206. 

Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin Neuropharmacol. Jul-Aug 2006;29(4):215-219.

Kraus PH, Lemke MR, Reichmann H. Kinetic tremor in Parkinson's disease--an underrated symptom. J Neural Transm. Jul 2006;113(7):845-853.

Lang AE, Houeto JL, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord. Jun 2006;21 Suppl 14:S171-196.

Lemke MR, Brecht HM, Koester J, Reichmann H. Effects of the dopamine agonist pramipexole on depression, anhedonia and motor functioning in Parkinson's disease. J Neurol Sci. Oct 25 2006;248(1-2):266-270.

Ma J, Wang YC, Gan SY. [Effects of electroacupuncture on behaviors and dopaminergic neurons in the rat of Parkinson's disease]. Zhongguo Zhen Jiu. Sep 2006;26(9):655-657.

Ma L, Zhang L, Gao XH, et al. Dietary factors and smoking as risk factors for PD in a rural population in China: a nested case-control study. Acta Neurol Scand. Apr 2006;113(4):278-281.

McLaughlin P, Zhou Y, Ma T, et al. Proteomic analysis of microglial contribution to mouse strain-dependent dopaminergic neurotoxicity. Glia. Apr 15 2006;53(6):567-582.

Mehler-Wex C, Riederer P, Gerlach M. Dopaminergic dysbalance in distinct basal ganglia neurocircuits: implications for the pathophysiology of Parkinson's disease, schizophrenia and attention deficit hyperactivity disorder. Neurotox Res. Dec 2006;10(3-4):167-179.

Morale MC, Serra PA, L'Episcopo F, et al. Estrogen, neuroinflammation and neuroprotection in Parkinson's disease: glia dictates resistance versus vulnerability to neurodegeneration. Neuroscience. 2006;138(3):869-878.

Muller T, Welnic J, Fuchs G, Baas H, Ebersbach G, Reichmann H. The DONPAD-study--treatment of dementia in patients with Parkinson's disease with donepezil. J Neural Transm Suppl. 2006(71):27-30.

Peralta C, Wolf E, Alber H, et al. Valvular heart disease in Parkinson's disease vs. controls: An echocardiographic study. Mov Disord. Aug 2006;21(8):1109-1113.

Poewe W. The need for neuroprotective therapies in Parkinson's disease: a clinical perspective. Neurology. May 23 2006;66(10 Suppl 4):S2-9.

Poewe W. The natural history of Parkinson's disease. J Neurol. Dec 2006;253 Suppl 7:VII2-6.

Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord. Apr 2006;21(4):456-461.

Portman AT, van Laar T, Staal MJ, Rutgers AW, Journee HL, Leenders KL. Chronic stimulation of the subthalamic nucleus increases daily on-time without dyskinesia in advanced Parkinson's disease. Parkinsonism Relat Disord. Apr 2006;12(3):143-148.

Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic Parkinsonian patients with and without dementia. An open-labeled study utilizing a structured interview. J Neurol. Feb 2006;253(2):171-175.

Reichmann H. Budipine in Parkinson's tremor. J Neurol Sci. Oct 25 2006;248(1-2):53-55.

Riederer P, Hoyer S. From benefit to damage. Glutamate and advanced glycation end products in Alzheimer brain. J Neural Transm. Nov 2006;113(11):1671-1677.

Rissling I, Frauscher B, Kronenberg F, et al. Daytime sleepiness and the COMT val158met polymorphism in patients with Parkinson disease. Sleep. Jan 1 2006;29(1):108-111.

Scherfler C, Khan NL, Pavese N, et al. Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations. Mov Disord. Jun 2006;21(6):783-788.

Scherfler C, Schocke MF, Seppi K, et al. Voxel-wise analysis of diffusion weighted imaging reveals disruption of the olfactory tract in Parkinson's disease. Brain. Feb 2006;129(Pt 2):538-542.

Scholz S, Mandel RJ, Fernandez HH, et al. LRRK2 mutations in a clinic-based cohort of Parkinson's disease. Eur J Neurol. Dec 2006;13(12):1298-1301.

Scholz SW, Xiromerisiou G, Fung HC, et al. The human prion gene M129V polymorphism is not associated with idiopathic Parkinson's disease in three distinct populations. Neurosci Lett. Mar 13 2006;395(3):227-229.

Schrag A, Geser F, Stampfer-Kountchev M, et al. Health-related quality of life in multiple system atrophy. Mov Disord. Jun 2006;21(6):809-815.

Schrag A, Sampaio C, Counsell N, Poewe W. Minimal clinically important change on the unified Parkinson's disease rating scale. Mov Disord. Aug 2006;21(8):1200-1207.

Seppi K, Hogl B, Diem A, Peralta C, Wenning GK, Poewe W. Levodopa-induced sleepiness in the Parkinson variant of multiple system atrophy. Mov Disord. Aug 2006;21(8):1281-1283.

Seppi K, Peralta C, Diem-Zangerl A, et al. Placebo-controlled trial of riluzole in multiple system atrophy. Eur J Neurol. Oct 2006;13(10):1146-1148.

Seppi K, Scherfler C, Donnemiller E, et al. Topography of dopamine transporter availability in progressive supranuclear palsy: a voxelwise [123I]beta-CIT SPECT analysis. Arch Neurol. Aug 2006;63(8):1154-1160.

Seppi K, Schocke MF, Mair KJ, et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage. May 15 2006;31(1):240-245.

Seppi K, Schocke MF, Prennschuetz-Schuetzenau K, et al. Topography of putaminal degeneration in multiple system atrophy: a diffusion magnetic resonance study. Mov Disord. Jun 2006;21(6):847-852.

Sharma M, Mueller JC, Zimprich A, et al. The sepiapterin reductase gene region reveals association in the PARK3 locus: analysis of familial and sporadic Parkinson's disease in European populations. J Med
Genet. Jul 2006;43(7):557-562. 

Shpirer I, Miniovitz A, Klein C, et al. Excessive daytime sleepiness in patients with Parkinson's disease: a polysomnography study. Mov Disord. Sep 2006;21(9):1432-1438.

Silveira-Moriyama L, Evans AH, Katzenschlager R, Lees AJ. Punding and dyskinesias. Mov Disord. Dec 2006;21(12):2214-2217.

Slevin JT, Gash DM, Smith CD, et al. Unilateral intraputaminal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year each of treatment and withdrawal. Neurosurg Focus. 2006;20(5):E1.

Smeding HM, Speelman JD, Koning-Haanstra M, et al. Neuropsychological effects of bilateral STN stimulation in Parkinson disease: a controlled study. Neurology. Jun 27 2006;66(12):1830-1836.

Sofic E, Sapcanin A, Tahirovic I, et al. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. J Neural Transm Suppl. 2006(71):39-43.

Stocchi F, Vacca L, Grassini P, et al. Symptom relief in Parkinson disease by safinamide: Biochemical and clinical evidence of efficacy beyond MAO-B inhibition. Neurology. Oct 10 2006;67(7 Suppl 2):S24-29.

Tang B, Xiong H, Sun P, et al. Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. Hum Mol Genet. Jun 1 2006;15(11):1816-1825.

Tehranian R, Montoya SE, Van Laar AD, Hastings TG, Perez RG. Alpha-synuclein inhibits aromatic amino acid decarboxylase activity in dopaminergic cells. J Neurochem. Nov 2006;99(4):1188-1196.

Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. Lancet Neurol. Jan 2006;5(1):75-86.

Tribl F, Marcus K, Bringmann G, Meyer HE, Gerlach M, Riederer P. Proteomics of the human brain: sub-proteomes might hold the key to handle brain complexity. J Neural Transm. Aug 2006;113(8):1041-1054.

Tribl F, Marcus K, Meyer HE, Bringmann G, Gerlach M, Riederer P. Subcellular proteomics reveals neuromelanin granules to be a lysosome-related organelle. J Neural Transm. Jun 2006;113(6):741-749.

Trost M, Su S, Su P, et al. Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. Neuroimage. May 15 2006;31(1):301-307.

Uehara T, Nakamura T, Yao D, et al. S-nitrosylated protein-disulphide isomerase links protein misfolding to neurodegeneration. Nature. May 25 2006;441(7092):513-517.

Wang F, Feng X, Ma J, Zou H, Chan P. A common A340T variant in PINK1 gene associated with late-onset Parkinson's disease in Chinese. Neurosci Lett. Dec 20 2006;410(2):121-125.

Wang YC, Ma J, Wang H. [Effects of Shuanggu Yitong needling method on proliferation and differentiation of nerve stem cells in the Parkinson's disease model rat]. Zhongguo Zhen Jiu. Apr 2006;26(4):277-282.

Wojtecki L, Timmermann L, Jorgens S, et al. Frequency-dependent reciprocal modulation of verbal fluency and motor functions in subthalamic deep brain stimulation. Arch Neurol. Sep 2006;63(9):1273-1276.

Wu T, Zeng Y, Ding X, et al. A novel P755L mutation in LRRK2 gene associated with Parkinson's disease. Neuroreport. Dec 18 2006;17(18):1859-1862.

Zamarian L, Visani P, Delazer M, et al. Parkinson's disease and arithmetics: the role of executive functions. J Neurol Sci. Oct 25 2006;248(1-2):124-130.

Zhang JG, Zhang K, Ma Y, et al. Follow-up of bilateral subthalamic deep brain stimulation for Parkinson's disease. Acta Neurochir Suppl. 2006;99:43-47.

2005

Alesch F. Sudden failure of dual channel pulse generators. Mov Disord. Jan 2005;20(1):64-66; discussion 66.

Asanuma K, Ma Y, Huang C, et al. The metabolic pathology of dopa-responsive dystonia. Ann Neurol. Apr 2005;57(4):596-600.

Berg D, Niwar M, Maass S, et al. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord. Sep 2005;20(9):1191-1194.

Berg D, Schweitzer K, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain. Dec 2005;128(Pt 12):3000-3011.

Castro A, Valldeoriola F, Linazasoro G, et al. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination.]. Neurologia. May 2005;20(4):180-188.

Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. Jan 29-Feb 4 2005;365(9457):412-415.

England A, Tam CL, Thacker DE, et al. Patterns, incidence and predictive factors for pain after interventional radiology. Clin Radiol. Nov 2005;60(11):1188-1194.

Fabbrini G, Brancati F, Vacca L, et al. A novel family with an unusual early-onset generalized dystonia. Mov Disord. Jan 2005;20(1):81-86.

Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol. Feb 2005;75(2):109-124.

Gerlach M, Reichmann H, Riederer P. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord. May 2005;20(5):643; author reply 643-644.

Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord. Aug 2005;20 Suppl 12:S11-20.

Gilad GM, Gilad VH, Finberg JP, Rabey JM. Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. Neurochem Res. Jun-Jul 2005;30(6-7):713-719.

Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. May 2005;20(5):523-539.

Haslinger B, Kalteis K, Boecker H, Alesch F, Ceballos-Baumann AO. Frequency-correlated decreases of motor cortex activity associated with subthalamic nucleus stimulation in Parkinson's disease. Neuroimage. Nov 15 2005;28(3):598-606.

Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry. Sep 2005;76(9):1217-1221.

Honer WG, Kopala LC, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol. May 2005;19(3):277-285.

Hummel T, Jahnke U, Sommer U, Reichmann H, Muller A. Olfactory function in patients with idiopathic Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm. May 2005;112(5):669-676.

Jellinger KA. Mortality in Parkinson's disease. Acta Neurol Scand. Jan 2005;111(1):71; author reply 72.

Jellinger KA. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol. Jun 2005;64(6):554.

Jellinger KA, Attems J. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci. Mar 15 2005;229-230:37-41.

Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. Feb 2005;20(2):151-157.

Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. Dec 2005;128(Pt 12):2786-2796.

Khan NL, Scherfler C, Graham E, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. Jan 11 2005;64(1):134-136.

Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm. Feb 2005;112(2):221-230.

Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. Feb 2005;57(2):176-179.

Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. Spring 2005;17(2):214-220.

Li GL, de Vries JJ, van Steeg TJ, et al. Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. J Control Release. Jan 3 2005;101(1-3):199-208.

Li J, Scheller C, Koutsilieri E, et al. Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem. Oct 2005;95(2):599-608.

Ma HI, Hwang WJ, Chen-Sea MJ. Reliability and validity testing of a Chinese-translated version of the 39-item Parkinson's Disease Questionnaire (PDQ-39). Qual Life Res. Mar 2005;14(2):565-569.

Mandel S, Grunblatt E, Riederer P, et al. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci. Aug 2005;1053:356-375.

Marchetti B, Serra PA, L'Episcopo F, et al. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Ann N Y Acad Sci. Dec 2005;1057:296-318.

Mueller A, Abolmaali ND, Hakimi AR, et al. Olfactory bulb volumes in patients with idiopathic Parkinson's disease a pilot study. J Neural Transm. Oct 2005;112(10):1363-1370.

Ostrem JL, Kang GA, Subramanian I, et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology. Apr 26 2005;64(8):1482.

Poblete Garcia V, Garcia Vicente A, Ruiz Solis S, et al. [SPECT with 123I-IBZM: utility in differential diagnosis of degenerative Parkinsonisms and establishment of quantification method]. Rev Esp Med Nucl. Jul-Aug 2005;24(4):234-243.

Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord. Aug 2005;20 Suppl 12:S77-82.

Poewe W, Luessi F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology. Jul 26 2005;65(2 Suppl 1):S11-14.

Puschban Z, Stefanova N, Petersen A, et al. Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. Brain Res Bull. Dec 15 2005;68(1-2):54-58.

Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once
daily, study): a randomised, double-blind, parallel-group trial. Lancet. Mar 12-18 2005;365(9463):947-954. 

Reichmann H. [Medication treatment for Parkinson's disease]. Nervenarzt. Dec 2005;76(12):1547-1557; quiz 1558.

Reichmann H. [The early therapy challenge]. Krankenpfl J. 2005;43(7-10):240.

Reichmann H, Angersbach D, Buchwald B. [Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study]. Nervenarzt. Oct 2005;76(10):1239-1240, 1242-1235.

Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. Jan 2005;111(1):21-28.

Sauermann S, Standhardt H, Gerschlager W, Lanmuller H, Alesch F. Kinematic evaluation in Parkinson's disease using a hand-held position transducer and computerized signal analysis. Acta Neurochir (Wien). Sep 2005;147(9):939-945; discussion 945.

Scherfler C, Sather T, Diguet E, et al. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). J Neural Transm. Aug 2005;112(8):1025-1033.

Scherfler C, Seppi K, Donnemiller E, et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain. Jul 2005;128(Pt 7):1605-1612.

Schmidauer C, Sojer M, Seppi K, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol. Oct 2005;58(4):630-634.

Seppi K, Schocke MF. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol. Aug 2005;18(4):370-375.

Seppi K, Schocke MF, Wenning GK, Poewe W. How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm. Dec 2005;112(12):1625-1634.

Seppi K, Yekhlef F, Diem A, et al. Progression of parkinsonism in multiple system atrophy. J Neurol. Jan 2005;252(1):91-96.

Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. Jun 2005;62(6):905-910.

Stryjer R, Klein C, Treves TA, Rabey JM. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients. Acta Neurol Scand. Feb 2005;111(2):89-94.

Tang K, Ma J, Zhang S. The anatomic and electrophysiological characters of the coronary sinus. Chin Med J (Engl). Mar 5 2005;118(5):404-408.

Tribl F, Gerlach M, Marcus K, et al. "Subcellular proteomics" of neuromelanin granules isolated from the human brain. Mol Cell Proteomics. Jul 2005;4(7):945-957.

von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol. Aug 2005;15(4):473-490.

Wang X, Chen S, Ma G, Ye M, Lu G. Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev. Dec 2005;126(12):1241-1254.

Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord. Oct 2005;20(10):1278-1285.

2004

Alesch F. Sudden failure of dual channel pulse generators. Mov Disord. Jan 2005;20(1):64-66; discussion 66.

Asanuma K, Ma Y, Huang C, et al. The metabolic pathology of dopa-responsive dystonia. Ann Neurol. Apr 2005;57(4):596-600.

Berg D, Niwar M, Maass S, et al. Alpha-synuclein and Parkinson's disease: implications from the screening of more than 1,900 patients. Mov Disord. Sep 2005;20(9):1191-1194.

Berg D, Schweitzer K, Leitner P, et al. Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain. Dec 2005;128(Pt 12):3000-3011.

Castro A, Valldeoriola F, Linazasoro G, et al. [Optimization of use of levodopa in Parkinson's disease: role of levodopa-carbidopa-entacapone combination.]. Neurologia. May 2005;20(4):180-188.

Di Fonzo A, Rohe CF, Ferreira J, et al. A frequent LRRK2 gene mutation associated with autosomal dominant Parkinson's disease. Lancet. Jan 29-Feb 4 2005;365(9457):412-415.

England A, Tam CL, Thacker DE, et al. Patterns, incidence and predictive factors for pain after interventional radiology. Clin Radiol. Nov 2005;60(11):1188-1194.

Fabbrini G, Brancati F, Vacca L, et al. A novel family with an unusual early-onset generalized dystonia. Mov Disord. Jan 2005;20(1):81-86.

Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Prog Neurobiol. Feb 2005;75(2):109-124.

Gerlach M, Reichmann H, Riederer P. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord. May 2005;20(5):643; author reply 643-644.

Geser F, Wenning GK, Poewe W, McKeith I. How to diagnose dementia with Lewy bodies: state of the art. Mov Disord. Aug 2005;20 Suppl 12:S11-20.

Gilad GM, Gilad VH, Finberg JP, Rabey JM. Neurochemical evidence for agmatine modulation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity. Neurochem Res. Jun-Jul 2005;30(6-7):713-719.

Goetz CG, Poewe W, Rascol O, Sampaio C. Evidence-based medical review update: pharmacological and surgical treatments of Parkinson's disease: 2001 to 2004. Mov Disord. May 2005;20(5):523-539.

Haslinger B, Kalteis K, Boecker H, Alesch F, Ceballos-Baumann AO. Frequency-correlated decreases of motor cortex activity associated with subthalamic nucleus stimulation in Parkinson's disease. Neuroimage. Nov 15 2005;28(3):598-606.

Hilker R, Portman AT, Voges J, et al. Disease progression continues in patients with advanced Parkinson's disease and effective subthalamic nucleus stimulation. J Neurol Neurosurg Psychiatry. Sep 2005;76(9):1217-1221.

Honer WG, Kopala LC, Rabinowitz J. Extrapyramidal symptoms and signs in first-episode, antipsychotic exposed and non-exposed patients with schizophrenia or related psychotic illness. J Psychopharmacol. May 2005;19(3):277-285.

Hummel T, Jahnke U, Sommer U, Reichmann H, Muller A. Olfactory function in patients with idiopathic Parkinson's disease: effects of deep brain stimulation in the subthalamic nucleus. J Neural Transm. May 2005;112(5):669-676.

Jellinger KA. Mortality in Parkinson's disease. Acta Neurol Scand. Jan 2005;111(1):71; author reply 72.

Jellinger KA. Alpha-synuclein lesions in normal aging, Parkinson disease, and Alzheimer disease: evidence from the Baltimore Longitudinal Study of Aging (BLSA). J Neuropathol Exp Neurol. Jun 2005;64(6):554.

Jellinger KA, Attems J. Prevalence and pathogenic role of cerebrovascular lesions in Alzheimer disease. J Neurol Sci. Mar 15 2005;229-230:37-41.

Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord. Feb 2005;20(2):151-157.

Khan NL, Jain S, Lynch JM, et al. Mutations in the gene LRRK2 encoding dardarin (PARK8) cause familial Parkinson's disease: clinical, pathological, olfactory and functional imaging and genetic data. Brain. Dec 2005;128(Pt 12):2786-2796.

Khan NL, Scherfler C, Graham E, et al. Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation. Neurology. Jan 11 2005;64(1):134-136.

Koller W, Guarnieri M, Hubble J, Rabinowicz AL, Silver D. An open-label evaluation of the tolerability and safety of Stalevo (carbidopa, levodopa and entacapone) in Parkinson's disease patients experiencing wearing-off. J Neural Transm. Feb 2005;112(2):221-230.

Kortekaas R, Leenders KL, van Oostrom JC, et al. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann Neurol. Feb 2005;57(2):176-179.

Lemke MR, Brecht HM, Koester J, Kraus PH, Reichmann H. Anhedonia, depression, and motor functioning in Parkinson's disease during treatment with pramipexole. J Neuropsychiatry Clin Neurosci. Spring 2005;17(2):214-220.

Li GL, de Vries JJ, van Steeg TJ, et al. Transdermal iontophoretic delivery of apomorphine in patients improved by surfactant formulation pretreatment. J Control Release. Jan 3 2005;101(1-3):199-208.

Li J, Scheller C, Koutsilieri E, et al. Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. J Neurochem. Oct 2005;95(2):599-608.

Ma HI, Hwang WJ, Chen-Sea MJ. Reliability and validity testing of a Chinese-translated version of the 39-item Parkinson's Disease Questionnaire (PDQ-39). Qual Life Res. Mar 2005;14(2):565-569.

Mandel S, Grunblatt E, Riederer P, et al. Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70. Ann N Y Acad Sci. Aug 2005;1053:356-375.

Marchetti B, Serra PA, L'Episcopo F, et al. Hormones are key actors in gene x environment interactions programming the vulnerability to Parkinson's disease: glia as a common final pathway. Ann N Y Acad Sci. Dec 2005;1057:296-318.

Mueller A, Abolmaali ND, Hakimi AR, et al. Olfactory bulb volumes in patients with idiopathic Parkinson's disease a pilot study. J Neural Transm. Oct 2005;112(10):1363-1370.

Ostrem JL, Kang GA, Subramanian I, et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology. Apr 26 2005;64(8):1482.

Poblete Garcia V, Garcia Vicente A, Ruiz Solis S, et al. [SPECT with 123I-IBZM: utility in differential diagnosis of degenerative Parkinsonisms and establishment of quantification method]. Rev Esp Med Nucl. Jul-Aug 2005;24(4):234-243.

Poewe W. Treatment of dementia with Lewy bodies and Parkinson's disease dementia. Mov Disord. Aug 2005;20 Suppl 12:S77-82.

Poewe W, Luessi F. Clinical studies with transdermal rotigotine in early Parkinson's disease. Neurology. Jul 26 2005;65(2 Suppl 1):S11-14.

Puschban Z, Stefanova N, Petersen A, et al. Evidence for dopaminergic re-innervation by embryonic allografts in an optimized rat model of the Parkinsonian variant of multiple system atrophy. Brain Res Bull. Dec 15 2005;68(1-2):54-58.

Rascol O, Brooks DJ, Melamed E, et al. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once

daily, study): a randomised, double-blind, parallel-group trial. Lancet. Mar 12-18 2005;365(9463):947-954.

Reichmann H. [Medication treatment for Parkinson's disease]. Nervenarzt. Dec 2005;76(12):1547-1557; quiz 1558.

Reichmann H. [The early therapy challenge]. Krankenpfl J. 2005;43(7-10):240.

Reichmann H, Angersbach D, Buchwald B. [Practical experience on improving activities of daily living competence in Parkinson's patients treated with ropinirole. Results of a applied study]. Nervenarzt. Oct 2005;76(10):1239-1240, 1242-1235.

Reichmann H, Boas J, Macmahon D, Myllyla V, Hakala A, Reinikainen K. Efficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuations. Acta Neurol Scand. Jan 2005;111(1):21-28.

Sauermann S, Standhardt H, Gerschlager W, Lanmuller H, Alesch F. Kinematic evaluation in Parkinson's disease using a hand-held position transducer and computerized signal analysis. Acta Neurochir (Wien). Sep 2005;147(9):939-945; discussion 945.

Scherfler C, Sather T, Diguet E, et al. Riluzole improves motor deficits and attenuates loss of striatal neurons in a sequential double lesion rat model of striatonigral degeneration (parkinson variant of multiple system atrophy). J Neural Transm. Aug 2005;112(8):1025-1033.

Scherfler C, Seppi K, Donnemiller E, et al. Voxel-wise analysis of [123I]beta-CIT SPECT differentiates the Parkinson variant of multiple system atrophy from idiopathic Parkinson's disease. Brain. Jul 2005;128(Pt 7):1605-1612.

Schmidauer C, Sojer M, Seppi K, et al. Transcranial ultrasound shows nigral hypoechogenicity in restless legs syndrome. Ann Neurol. Oct 2005;58(4):630-634.

Seppi K, Schocke MF. An update on conventional and advanced magnetic resonance imaging techniques in the differential diagnosis of neurodegenerative parkinsonism. Curr Opin Neurol. Aug 2005;18(4):370-375.

Seppi K, Schocke MF, Wenning GK, Poewe W. How to diagnose MSA early: the role of magnetic resonance imaging. J Neural Transm. Dec 2005;112(12):1625-1634.

Seppi K, Yekhlef F, Diem A, et al. Progression of parkinsonism in multiple system atrophy. J Neurol. Jan 2005;252(1):91-96.

Stocchi F, Vacca L, Ruggieri S, Olanow CW. Intermittent vs continuous levodopa administration in patients with advanced Parkinson disease: a clinical and pharmacokinetic study. Arch Neurol. Jun 2005;62(6):905-910.

Stryjer R, Klein C, Treves TA, Rabey JM. The effects of acute loading with levodopa and levodopa with selegiline on blood pressure and plasma norepinephrine levels in chronic Parkinson's disease patients. Acta Neurol Scand. Feb 2005;111(2):89-94.

Tang K, Ma J, Zhang S. The anatomic and electrophysiological characters of the coronary sinus. Chin Med J (Engl). Mar 5 2005;118(5):404-408.

Tribl F, Gerlach M, Marcus K, et al. "Subcellular proteomics" of neuromelanin granules isolated from the human brain. Mol Cell Proteomics. Jul 2005;4(7):945-957.

von Campenhausen S, Bornschein B, Wick R, et al. Prevalence and incidence of Parkinson's disease in Europe. Eur Neuropsychopharmacol. Aug 2005;15(4):473-490.

Wang X, Chen S, Ma G, Ye M, Lu G. Involvement of proinflammatory factors, apoptosis, caspase-3 activation and Ca2+ disturbance in microglia activation-mediated dopaminergic cell degeneration. Mech Ageing Dev. Dec 2005;126(12):1241-1254.

Zecca L, Berg D, Arzberger T, et al. In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage. Mov Disord. Oct 2005;20(10):1278-1285.

2003

Berding G, Brucke T, Odin P, et al. [[123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinson's disease and multiple system atrophy. Nuklearmedizin. Feb 2003;42(1):31-38.

Berg E, Bjornram C, Hartelius L, Laakso K, Johnels B. High-level language difficulties in Parkinson's disease. Clin Linguist Phon. Jan-Feb 2003;17(1):63-80.

Brenneis C, Seppi K, Schocke MF, et al. Voxel-based morphometry detects cortical atrophy in the Parkinson variant of multiple system atrophy. Mov Disord. Oct 2003;18(10):1132-1138.

de Swart BJ, Willemse SC, Maassen BA, Horstink MW. Improvement of voicing in patients with Parkinson's disease by speech therapy. Neurology. Feb 11 2003;60(3):498-500.

Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ. Tremor in Parkinson's disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology. Feb 25 2003;60(4):601-605.

Double KL, Gerlach M, Schunemann V, et al. Iron-binding characteristics of neuromelanin of the human substantia nigra. Biochem Pharmacol. Aug 1 2003;66(3):489-494.

Gerlach M, Double K, Arzberger T, Leblhuber F, Tatschner T, Riederer P. Dopamine receptor agonists in current clinical use: comparative dopamine receptor binding profiles defined in the human striatum. J Neural Transm. Oct 2003;110(10):1119-1127.

Gerlach M, Double K, Reichmann H, Riederer P. Arguments for the use of dopamine receptor agonists in clinical and preclinical Parkinson's disease. J Neural Transm Suppl. 2003(65):167-183.

Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Neurotox Res. 2003;5(1-2):35-44.

Gerlach M, Foley P, Riederer P. The relevance of preclinical studies for the treatment of Parkinson's disease. J Neurol. Feb 2003;250 Suppl 1:I31-34.

Gerlach M, Riederer P. [Current preclinical findings on substances against Parkinson's disease]. Nervenarzt. Mar 2003;74 Suppl 1:S2-6.

Grunblatt E, Schlosser R, Gerlach M, Riederer P. Preclinical versus clinical neuroprotection. Adv Neurol. 2003;91:309-328.

Happe S, Pirker W, Klosch G, Sauter C, Zeitlhofer J. Periodic leg movements in patients with Parkinson's disease are associated with reduced striatal dopamine transporter binding. J Neurol. Jan 2003;250(1):83-86.

Hogl B, Rothdach A, Wetter TC, Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology. Oct 2003;28(10):1866-1870.

Hogl B, Seppi K, Brandauer E, et al. Increased daytime sleepiness in Parkinson's disease: a questionnaire survey. Mov Disord. Mar 2003;18(3):319-323.

Holler I, Dirnberger G, Pirker W, Auff E, Gerschlager W. Camptocormia in idiopathic Parkinson's disease: [(123)I]beta-CIT SPECT and clinical characteristics. Eur Neurol. 2003;50(2):118-120.

Homann CN, Homann B, Ott E, Park KB. Sleep attacks may not be a side effect of dopaminergic medication. Mov Disord. Dec 2003;18(12):1569-1570; author reply 1571.

Homann CN, Suppan K, Homann B, Crevenna R, Ivanic G, Ruzicka E. Driving in Parkinson's disease - a health hazard? J Neurol. Dec 2003;250(12):1439-1446.

Homann CN, Wenzel K, Suppan K, Ivanic G, Crevenna R, Ott E. Sleep attacks--facts and fiction: a critical review. Adv Neurol. 2003;91:335-341.

Huang YA, Yin Z, Zhang BG, et al. [Stereotactic microelectrode-guided posteroventral pallidotomy for Parkinson's disease]. Zhonghua Wai Ke Za Zhi. Feb 2003;41(2):106-108.

Jacobs AH, Li H, Winkeler A, et al. PET-based molecular imaging in neuroscience. Eur J Nucl Med Mol Imaging. Jul 2003;30(7):1051-1065.

Jellinger K. The association of incident dementia with mortality in PD. Neurology. Aug 12 2003;61(3):424.

Jellinger KA. Prevalence of cerebrovascular lesions in Parkinson's disease. A postmortem study. Acta Neuropathol (Berl). May 2003;105(5):415-419.

Jellinger KA. Prevalence of stroke in Parkinson's disease. Mov Disord. Jun 2003;18(6):723-724.

Jellinger KA. How valid is the clinical diagnosis of Parkinson's disease in the community? J Neurol Neurosurg Psychiatry. Jul 2003;74(7):1005-1006.

Jellinger KA. Prevalence of vascular lesions in dementia with Lewy bodies. A postmortem study. J Neural Transm. Jul 2003;110(7):771-778.

Jellinger KA. Alpha-synuclein pathology in Parkinson's and Alzheimer's disease brain: incidence and topographic distribution--a pilot study. Acta Neuropathol (Berl). Sep 2003;106(3):191-201.

Jellinger KA. Age-associated prevalence and risk factors of Lewy body pathology in a general population. Acta Neuropathol (Berl). Oct 2003;106(4):383-384.

Jellinger KA. Prevalence of Alzheimer lesions in Parkinson's disease. Mov Disord. Oct 2003;18(10):1207-1208.

Jellinger KA. Parkinson disease with old-age onset. Arch Neurol. Dec 2003;60(12):1814-1815.

Jellinger KA, Mitter-Ferstl E. The impact of cerebrovascular lesions in Alzheimer disease--a comparative autopsy study. J Neurol. Sep 2003;250(9):1050-1055.

Jellinger KA, Seppi K, Wenning GK. Neuropathologic changes in Parkinson disease with late onset of dementia. Arch Neurol. Mar 2003;60(3):452-453; author reply 453-454.

Katzenschlager R, Sampaio C, Costa J, Lees A. Anticholinergics for symptomatic management of Parkinson's disease. Cochrane Database Syst Rev. 2003(2):CD003735.

Klein C, Gordon J, Pollak L, Rabey JM. Clozapine in Parkinson's disease psychosis: 5-year follow-up review. Clin Neuropharmacol. Jan-Feb 2003;26(1):8-11.

Kofler M, Muller J, Seppi K, Wenning GK. Exaggerated auditory startle responses in multiple system atrophy: a comparative study of parkinson and cerebellar subtypes. Clin Neurophysiol. Mar 2003;114(3):541-547.

Lampe JB, Gossrau G, Herting B, et al. HLA typing and Parkinson's disease. Eur Neurol. 2003;50(2):64-68.

Lange KW, Tucha O, Alders GL, et al. Differentiation of parkinsonian syndromes according to differences in executive functions. J Neural Transm. Sep 2003;110(9):983-995.

Leblhuber F, Neurauter G, Fuchs D. Oxidative damage and cytogenic analysis in leukocytes of Parkinson's disease patients. Neurology. Feb 25 2003;60(4):729; author reply 729.

Lynch DR, Mozley PD, Sokol S, Maas NM, Balcer LJ, Siderowf AD. Lack of effect of polymorphisms in dopamine metabolism related genes on imaging of TRODAT-1 in striatum of asymptomatic volunteers and patients with Parkinson's disease. Mov Disord. Jul 2003;18(7):804-812.

Mandel S, Grunblatt E, Riederer P, Gerlach M, Levites Y, Youdim MB. Neuroprotective strategies in Parkinson's disease : an update on progress. CNS Drugs. 2003;17(10):729-762.

Muller JL, Deuticke C, Putzhammer A, Roder CH, Hajak G, Winkler J. Schizophrenia and Parkinson's disease lead to equal motor-related changes in cortical and subcortical brain activation: an fMRI fingertapping study. Psychiatry Clin Neurosci. Dec 2003;57(6):562-568.

Pirker W. Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it? Mov Disord. Oct 2003;18 Suppl 7:S43-51.

Pirker W, Holler I, Gerschlager W, Asenbaum S, Zettinig G, Brucke T. Measuring the rate of progression of Parkinson's disease over a 5-year period with beta-CIT SPECT. Mov Disord. Nov 2003;18(11):1266-1272.

Poewe W. Psychosis in Parkinson's disease. Mov Disord. Sep 2003;18 Suppl 6:S80-87.

Poewe W, Scherfler C. Role of dopamine transporter imaging in investigation of parkinsonian syndromes in routine clinical practice. Mov Disord. Oct 2003;18 Suppl 7:S16-21.

Reichmann H, Brecht MH, Koster J, Kraus PH, Lemke MR. Pramipexole in routine clinical practice: a prospective observational trial in Parkinson's disease. CNS Drugs. 2003;17(13):965-973.

Reichmann H, Gossrau G, Sommer U. [New approaches to transplantation of dopamine-producing cells and stem cells]. Nervenarzt. Mar 2003;74 Suppl 1:S22-26.

Reichmann H, Herting B, Miller A, Sommer U. Switching and combining dopamine agonists. J Neural Transm. Dec 2003;110(12):1393-1400.

Riederer P. Is there a subtype of developmental Parkinson's disease? Neurotox Res. 2003;5(1-2):27-34.

Riederer P, Lachenmayer L. Selegiline's neuroprotective capacity revisited. J Neural Transm. Nov 2003;110(11):1273-1278.

Seppi K, Schocke MF, Esterhammer R, et al. Diffusion-weighted imaging discriminates progressive supranuclear palsy from PD, but not from the parkinson variant of multiple system atrophy. Neurology. Mar 25 2003;60(6):922-927.

Sommer U, Reichmann H. [Early detection of Parkinson syndrome]. Orthopade. Jan 2003;32(1):82-84.

Stocchi F, Berardelli A, Vacca L, et al. Apomorphine infusion and the long-duration response to levodopa in advanced Parkinson's disease. Clin Neuropharmacol. May-Jun 2003;26(3):151-155.

Stocchi F, Vacca L, Berardelli A, Onofrj M, Manfredi M, Ruggieri S. Dual dopamine agonist treatment in Parkinson's disease. J Neurol. Jul 2003;250(7):822-826.

Stocchi F, Vacca L, Grassini P, et al. Optimizing levodopa pharmacokinetics in Parkinson's disease: the role of COMT inhibitor. Neurol Sci. Oct 2003;24(3):217-218.

Stocchi F, Vacca L, Onofrj M. Are there clinically significant differences between dopamine agonists. Adv Neurol. 2003;91:259-266.

Trost M, Su PC, Barnes A, et al. Evolving metabolic changes during the first postoperative year after subthalamotomy. J Neurosurg. Nov 2003;99(5):872-878.

Vaamonde J, Ibanez R, Gudin M, Hernandez A. [Fluctuations and dyskinesias as early L-dopa-induced motor complications in severe Parkinsonian's patients]. Neurologia. Apr 2003;18(3):162-165.

van Laar T. Levodopa-induced response fluctuations in patients with Parkinson's disease: strategies for management. CNS Drugs. 2003;17(7):475-489.

Werber E, Klein C, Grunfeld J, Rabey JM. Phenotypic presentation of frontotemporal dementia with Parkinsonism-chromosome 17 type P301S in a patient of Jewish-Algerian origin. Mov Disord. May 2003;18(5):595-598.

Whitehill TL, Ma JK, Lee AS. Perceptual characteristics of Cantonese hypokinetic dysarthria. Clin Linguist Phon. Jun-Aug 2003;17(4-5):265-271.

Whone AL, Watts RL, Stoessl AJ, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. Jul 2003;54(1):93-101.

Zecca L, Zucca FA, Costi P, et al. The neuromelanin of human substantia nigra: structure, synthesis and molecular behaviour. J Neural Transm Suppl. 2003(65):145-155.

Zimprich A, Asmus F, Leitner P, et al. Point mutations in exon 1 of the NR4A2 gene are not a major cause of familial Parkinson's disease. Neurogenetics. Aug 2003;4(4):219-220.

2002

Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a
randomised controlled study. J Neurol Neurosurg Psychiatry. Jun 2002;72(6):708-712. 

Acuna G, Foernzler D, Leong D, et al. Pharmacogenetic analysis of adverse drug effect reveals genetic variant for susceptibility to liver toxicity. Pharmacogenomics J. 2002;2(5):327-334.

Baron MS, Wichmann T, Ma D, DeLong MR. Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J Neurosci. Jan 15 2002;22(2):592-599.
 
Bayer AU, Keller ON, Ferrari F, Maag KP. Association of glaucoma with neurodegenerative diseases with apoptotic cell death: Alzheimer's disease and Parkinson's disease. Am J Ophthalmol. Jan 2002;133(1):135-137. 

Boesch SM, Wenning GK, Ransmayr G, Poewe W. Dystonia in multiple system atrophy. J Neurol Neurosurg Psychiatry. Mar 2002;72(3):300-303.

Brunner H, Wetter TC, Hogl B, Yassouridis A, Trenkwalder C, Friess E. Microstructure of the non-rapid eye movement sleep electroencephalogram in patients with newly diagnosed Parkinson's disease: effects of dopaminergic treatment. Mov Disord. Sep 2002;17(5):928-933.

Chaudhuri KR, Pal S, DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry. Dec 2002;73(6):629-635.

Dhawan V, Ma Y, Pillai V, et al. Comparative analysis of striatal FDOPA uptake in Parkinson's disease: ratio method versus graphical approach. J Nucl Med. Oct 2002;43(10):1324-1330.

Ebersbach G, Sojer M, Muller J, Ransmayr G, Wenning G, Poewe W. [Dysequilibrium in idiopathic Parkinson disease. The effect of cerebrovascular comorbidity]. Nervenarzt. Feb 2002;73(2):162-165.

Gerlach M, Stadler K, Aichner F, Ransmayr G. Dementia with Lewy bodies and AD are not associated with occipital lobe atrophy on MRI. Neurology. Nov 12 2002;59(9):1476.

Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinson's disease. Mov Disord. May 2002;17(3):518-523.

Goldberg JA, Boraud T, Maraton S, Haber SN, Vaadia E, Bergman H. Enhanced synchrony among primary motor cortex neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. J Neurosci. Jun 1 2002;22(11):4639-4653.

Hamilton GS, Wu YQ, Limburg DC, et al. Synthesis of N-glyoxyl prolyl and pipecolyl amides and thioesters and evaluation of their in vitro and in vivo nerve regenerative effects. J Med Chem. Aug 1 2002;45(16):3549-3557.

Hogl B, Saletu M, Brandauer E, et al. Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial. Sleep. Dec 2002;25(8):905-909.

Homann CN, Forstner M, Ivanic G, Ott E. Daytime sleepiness and other sleep disorders in Parkinson's disease. Neurology. Jun 25 2002;58(12):1863; author reply 1863-1864.

Homann CN, Suppan K, Wenzel K, Ivanic G, Kriechbaum N, Ott E. Sleep attacks with apomorphine. Wien Klin Wochenschr. Jun 14 2002;114(10-11):430-431.

Homann CN, Wenzel K, Suppan K, et al. Sleep attacks in patients taking dopamine agonists: review. Bmj. Jun 22 2002;324(7352):1483-1487.

Jellinger KA. Disturbance of the nigro-amygdaloid connections in dementia with Lewy bodies. J Neurol Sci. Jan 15 2002;193(2):157-158.

Jellinger KA. Recent developments in the pathology of Parkinson's disease. J Neural Transm Suppl. 2002(62):347-376.

Jellinger KA, Seppi K, Wenning GK. Lewy bodies in patients presenting clinically with Alzheimer disease. J Alzheimers Dis. Aug 2002;4(4):327-328.

Jellinger KA, Seppi K, Wenning GK, Poewe W. Impact of coexistent Alzheimer pathology on the natural history of Parkinson's disease. J Neural Transm. Mar 2002;109(3):329-339.

Katzenschlager R, Costa D, Gacinovic S, Lees AJ. [(123)I]-FP-CIT-SPECT in the early diagnosis of PD presenting as exercise-induced dystonia. Neurology. Dec 24 2002;59(12):1974-1976.

Katzenschlager R, Lees AJ. Treatment of Parkinson's disease: levodopa as the first choice. J Neurol. Sep 2002;249 Suppl 2:II19-24.

Koutsilieri E, Scheller C, Grunblatt E, Nara K, Li J, Riederer P. Free radicals in Parkinson's disease. J Neurol. Sep 2002;249 Suppl 2:II1-5.

Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P. Involvement of dopamine in the progression of AIDS Dementia Complex. J Neural Transm. Mar 2002;109(3):399-410.

Kushnir M, Klein C, Pollak L, Rabey JM. H reflex threshold in Parkinson's disease patients for different stimulus duration. Parkinsonism Relat Disord. Dec 2002;9(2):85-87.

Ling Z, Gayle DA, Ma SY, et al. In utero bacterial endotoxin exposure causes loss of tyrosine hydroxylase neurons in the postnatal rat midbrain. Mov Disord. Jan 2002;17(1):116-124.

Ma Y, Dhawan V, Mentis M, Chaly T, Spetsieris PG, Eidelberg D. Parametric mapping of [18F]FPCIT binding in early stage Parkinson's disease: a PET study. Synapse. Aug 2002;45(2):125-133.

Marinus J, Visser M, Stiggelbout AM, et al. Activity-based diary for Parkinson's disease. Clin Neuropharmacol. Jan-Feb 2002;25(1):43-50.

Muller A, Mungersdorf M, Reichmann H, Strehle G, Hummel T. Olfactory function in Parkinsonian syndromes. J Clin Neurosci. Sep 2002;9(5):521-524.

Muller A, Reichmann H, Livermore A, Hummel T. Olfactory function in idiopathic Parkinson's disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de-novo IPD patients. J Neural Transm. May 2002;109(5-6):805-811.

Palfi S, Leventhal L, Chu Y, et al. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci. Jun 15 2002;22(12):4942-4954.

Poewe W, Wenning G. The differential diagnosis of Parkinson's disease. Eur J Neurol. Nov 2002;9 Suppl 3:23-30.

Poewe WH, Deuschl G, Gordin A, Kultalahti ER, Leinonen M. Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study). Acta Neurol Scand. Apr 2002;105(4):245-255.

Przuntek H, Bittkau S, Bliesath H, et al. Budipine provides additional benefit in patients with Parkinson disease receiving a stable optimum dopaminergic drug regimen. Arch Neurol. May 2002;59(5):803-806.

Rabey JM, Klein C, Molochnikov A, Van Hilten B, Krauss P, Bonuccelli U. Comparison of the Unified Parkinson's Disease Rating Scale and the Short Parkinson's Evaluation Scale in patients with Parkinson's disease after levodopa loading. Clin Neuropharmacol. Mar-Apr 2002;25(2):83-88.

Rascol O, Goetz C, Koller W, Poewe W, Sampaio C. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet. May 4 2002;359(9317):1589-1598.

Reichmann H. Neuroprotection in idiopathic Parkinson's disease. J Neurol. Oct 2002;249 Suppl 3:III/21-23.

Reichmann H, Brecht HM, Kraus PH, Lemke MR. [Pramipexole in Parkinson disease. Results of a treatment observation]. Nervenarzt. Aug 2002;73(8):745-750.

Richter G, Sonnenschein A, Grunewald T, Reichmann H, Janetzky B. Novel mitochondrial DNA mutations in Parkinson's disease. J Neural Transm. May 2002;109(5-6):721-729.

Riederer P, Foley P. Mini-review: multiple developmental forms of parkinsonism. The basis for further research as to the pathogenesis of parkinsonism. J Neural Transm. Dec 2002;109(12):1469-1475.

Riederer P, Gille G, Muller T, et al. Practical importance of neuroprotection in Parkinson's disease. J Neurol. Oct 2002;249 Suppl 3:III/53-56. 

Scherfler C, Donnemiller E, Schocke M, et al. Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. Neuroimage. Sep 2002;17(1):128-141. 

Schocke MF, Seppi K, Esterhammer R, et al. Diffusion-weighted MRI differentiates the Parkinson variant of multiple system atrophy from PD. Neurology. Feb 26 2002;58(4):575-580. 

Sommer U, Muller A, Herting B, Cormann K, Kohlert F, Reichmann H. [Entacapone for treatment of motor fluctuations in idiopathic Parkinson syndrome]. Nervenarzt. Aug 2002;73(8):761-764. 

Stocchi F, Berardelli A, Vacca L, et al. Combination of two different dopamine agonists in the management of Parkinson's disease. Neurol Sci. Sep 2002;23 Suppl 2:S115-116. 

Stocchi F, Ruggieri S, Vacca L, Olanow CW. Prospective randomized trial of lisuride infusion versus oral levodopa in patients with Parkinson's disease. Brain. Sep 2002;125(Pt 9):2058-2066. 

Stryjer R, Bar F, Strous RD, Baruch Y, Rabey JM. Donepezil management of schizophrenia with associated dementia. J Clin Psychopharmacol. Apr 2002;22(2):226-229. 

Szabolcs MJ, Sun J, Ma N, et al. Effects of selective inhibitors of nitric oxide synthase-2 dimerization on acute cardiac allograft rejection. Circulation. Oct 29 2002;106(18):2392-2396. 

Thommessen B, Aarsland D, Braekhus A, Oksengaard AR, Engedal K, Laake K. The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease. Int J Geriatr Psychiatry. Jan 2002;17(1):78-84. 

Tison F, Yekhlef F, Balestre E, et al. Application of the International Cooperative Ataxia Scale rating in multiple system atrophy. Mov Disord. Nov 2002;17(6):1248-1254. 

Widner B, Leblhuber F, Frick B, Laich A, Artner-Dworzak E, Fuchs D. Moderate hyperhomocysteinaemia and immune activation in Parkinson's disease. J Neural Transm. Dec 2002;109(12):1445-1452. 

Widner B, Leblhuber F, Fuchs D. Increased neopterin production and tryptophan degradation in advanced Parkinson's disease. J Neural Transm. Feb 2002;109(2):181-189. 

Zecca L, Fariello R, Riederer P, Sulzer D, Gatti A, Tampellini D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout the life and is dramatically decreased in Parkinson's disease. FEBS Lett. Jan 16 2002;510(3):216-220.

2001

Albanese A, Bonuccelli U, Brefel C, et al. Consensus statement on the role of acute dopaminergic challenge in Parkinson's disease. Mov Disord. Mar 2001;16(2):197-201. 

Berg D, Gerlach M, Youdim MB, et al. Brain iron pathways and their relevance to Parkinson's disease. J Neurochem. Oct 2001;79(2):225-236. 

Cunnington R, Lalouschek W, Dirnberger G, et al. A medial to lateral shift in pre-movement cortical activity in hemi-Parkinson's disease. Clin Neurophysiol. Apr 2001;112(4):608-618. 

Fukuda M, Mentis MJ, Ma Y, et al. Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: a PET study of resting-state glucose metabolism. Brain. Aug 2001;124(Pt 8):1601-1609.

Gerschlager W, Bloem BR, Alesch F, Lang W, Deecke L, Cunnington R. Bilateral subthalamic nucleus stimulation does not improve prolonged P300 latencies in Parkinson's disease. J Neurol. Apr 2001;248(4):285-289. 

Haasio K, Sopanen L, Vaalavirta L, Linden IB, Heinonen EH. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J Neural Transm. 2001;108(1):79-91. 

Happe S, Pirker W, Sauter C, Klosch G, Zeitlhofer J. Successful treatment of excessive daytime sleepiness in Parkinson's disease with modafinil. J Neurol. Jul 2001;248(7):632-634. 

Happe S, Schrodl B, Faltl M, Muller C, Auff E, Zeitlhofer J. Sleep disorders and depression in patients with Parkinson's disease. Acta Neurol Scand. Nov 2001;104(5):275-280. 

Hogl B, Peralta C, Wetter TC, Gershanik O, Trenkwalder C. Effect of sleep deprivation on motor performance in patients with Parkinson's disease. Mov Disord. Jul 2001;16(4):616-621. 

Hogl B, Wetter TC, Trenkwalder C. [Pathophysiology, clinical aspects and therapy of sleep disorders in Parkinson disease]. Nervenarzt. Jun 2001;72(6):416-424. 

Jansen PA, Herings RM, Samson MM, et al. Quick titration of pergolide in cotreatment with domperidone is safe and effective. Clin Neuropharmacol. May-Jun 2001;24(3):177-180. 

Jellinger KA. The pathology of Parkinson's disease. Adv Neurol. 2001;86:55-72. 

Jellinger KA. Influenza RNA not detected in archival brain tissues from acute encephalitis lethargica cases or in postencephalitic Parkinson cases. J Neuropathol Exp Neurol. Nov 2001;60(11):1121-1122. 

Jellinger KA. Cell death mechanisms in neurodegeneration. J Cell Mol Med. Jan-Mar 2001;5(1):1-17. 

Kofler M, Muller J, Wenning GK, et al. The auditory startle reaction in parkinsonian disorders. Mov Disord. Jan 2001;16(1):62-71. 

Koornstra JJ, Klaver NS, ter Maaten JC, Limburg AJ, van der Jagt EJ, van der Werf TS. [Neostigmine treatment of acute pseudo-obstruction of colon (Ogilvie syndrome)]. Ned Tijdschr Geneeskd. Mar 24 2001;145(12):586-589. 

Korten A, Lodder J, Vreeling F, Boreas A, van Raak L, Kessels F. Stroke and idiopathic Parkinson's disease: does a shortage of dopamine offer protection against stroke? Mov Disord. Jan 2001;16(1):119-123. 

Koutsilieri E, ter Meulen V, Riederer P. Neurotransmission in HIV associated dementia: a short review. J Neural Transm. 2001;108(6):767-775. 

Kushnir M, Klein C, Rabey JM. H reflex behavior in Parkinson's disease patients and patients with extrapyramidal and pyramidal signs combined. J Neurol Sci. May 1 2001;186(1-2):101-105. 

Lees AJ, Katzenschlager R, Head J, Ben-Shlomo Y. Ten-year follow-up of three different initial treatments in de-novo PD: a randomized trial. Neurology. Nov 13 2001;57(9):1687-1694.

Marras C, Lang AE, Ang LC, Zijlmans J, Wenning GK. 69-year-old man with gait disturbance and Parkinsonism. Mov Disord. May 2001;16(3):548-561. 

Mossner R, Henneberg A, Schmitt A, et al. Allelic variation of serotonin transporter expression is associated with depression in Parkinson's disease. Mol Psychiatry. May 2001;6(3):350-352. 

Muller J, Wenning GK, Verny M, et al. Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol. Feb 2001;58(2):259-264. 

Mungersdorf M, Sommer U, Sommer M, Reichmann H. High-dose therapy with ropinirole in patients with Parkinson's disease. J Neural Transm. 2001;108(11):1309-1317. 

Nakamura T, Dhawan V, Chaly T, et al. Blinded positron emission tomography study of dopamine cell implantation for Parkinson's disease. Ann Neurol. Aug 2001;50(2):181-187. 

Oertel WH, Hoglinger GU, Caraceni T, et al. Depression in Parkinson's disease. An update. Adv Neurol. 2001;86:373-383. 

Oliveri RL, Zappia M, Annesi G, et al. The parkin gene is not involved in late-onset Parkinson's disease. Neurology. Jul 24 2001;57(2):359-362. 

Pirker W, Tedroff J, Ponten H, Gunne L, Andren PE, Hurd YL. Coadministration of (-)-OSU6162 with l-DOPA normalizes preproenkephalin mRNA expression in the sensorimotor striatum of primates with unilateral 6-OHDA lesions. Exp Neurol. May 2001;169(1):122-134. 

Poewe W, Seppi K. Treatment options for depression and psychosis in Parkinson's disease. J Neurol. Sep 2001;248 Suppl 3:III12-21. 

Ransmayr G, Seppi K, Donnemiller E, et al. Striatal dopamine transporter function in dementia with Lewy bodies and Parkinson's disease. Eur J Nucl Med. Oct 2001;28(10):1523-1528. 

Raz A, Frechter-Mazar V, Feingold A, Abeles M, Vaadia E, Bergman H. Activity of pallidal and striatal tonically active neurons is correlated in mptp-treated monkeys but not in normal monkeys. J Neurosci. Feb 1 2001;21(3):RC128. 

Riederer P, Reichmann H, Janetzky B, et al. Neural degeneration in Parkinson's disease. Adv Neurol. 2001;86:125-136. 

Stefanova N, Klimaschewski L, Poewe W, Wenning GK, Reindl M. Glial cell death induced by overexpression of alpha-synuclein. J Neurosci Res. Sep 1 2001;65(5):432-438. 

Stocchi F, Vacca L, Berardelli A, De Pandis F, Ruggieri S. Long-duration effect and the postsynaptic compartment: study using a dopamine agonist with a short half-life. Mov Disord. Mar 2001;16(2):301-305. 

Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, Ruggieri S. Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: long-term results. Neurol Sci. Feb 2001;22(1):93-94. 

Stocchi F, Vacca L, Valente M, Ruggieri S. Sleep disorders in Parkinson's disease. Adv Neurol. 2001;86:289-293. 

Su PC, Ma Y, Fukuda M, et al. Metabolic changes following subthalamotomy for advanced Parkinson's disease. Ann Neurol. Oct 2001;50(4):514-520. 

Tribl GG, Wober C, Schonborn V, Brucke T, Deecke L, Panzer S. Amantadine in Parkinson's disease: lymphocyte subsets and IL-2 secreting T cell precursor frequencies. Exp Gerontol. Nov 2001;36(10):1761-1771. 

Vaamonde J, Ibanez R, Hernandez A, Gudin M, de Luis P, del Real MA. [Motor impairment, in patients with severe Parkinson's disease, associated with dopaminergic hyperstimulation (entacapone)]. Neurologia. Feb 2001;16(2):81-84. 

Vogel G. Parkinson's research. Fetal cell transplant trial draws fire. Science. Mar 16 2001;291(5511):2060-2061. 

Werber EA, Rabey JM. The beneficial effect of cholinesterase inhibitors on patients suffering from Parkinson's disease and dementia. J Neural Transm. 2001;108(11):1319-1325. 

Wetter TC, Brunner H, Hogl B, Yassouridis A, Trenkwalder C, Friess E. Increased alpha activity in REM sleep in de novo patients with Parkinson's disease. Mov Disord. Sep 2001;16(5):928-933. 

Wetter TC, Trenkwalder C, Gershanik O, Hogl B. Polysomnographic measures in Parkinson's disease: a comparison between patients with and without REM sleep disturbances. Wien Klin Wochenschr. Apr 17 2001;113(7-8):249-253. 

Zecca L, Tampellini D, Gerlach M, Riederer P, Fariello RG, Sulzer D. Substantia nigra neuromelanin: structure, synthesis, and molecular behaviour. Mol Pathol. Dec 2001;54(6):414-418.

2000

1999

Aarsland D, Larsen JP, Cummins JL, Laake K. Prevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based study. Arch Neurol. May 1999;56(5):595-601. 

Agid Y, Ahlskog E, Albanese A, et al. Levodopa in the treatment of Parkinson's disease: a consensus meeting. Mov Disord. Nov 1999;14(6):911-913. 

Berg D, Grote C, Rausch WD, et al. Iron accumulation in the substantia nigra in rats visualized by ultrasound. Ultrasound Med Biol. Jul 1999;25(6):901-904. 

Ceballos-Baumann AO, Boecker H, Bartenstein P, et al. A positron emission tomographic study of subthalamic nucleus stimulation in Parkinson disease: enhanced movement-related activity of motor-association cortex and decreased motor cortex resting activity. Arch Neurol. Aug 1999;56(8):997-1003. 

De Coo IF, Renier WO, Ruitenbeek W, et al. A 4-base pair deletion in the mitochondrial cytochrome b gene associated with parkinsonism/MELAS overlap syndrome. Ann Neurol. Jan 1999;45(1):130-133. 

Double KL, Riederer PF, Gerlach M. Role of iron in 6-hydroxydopamine neurotoxicity. Adv Neurol. 1999;80:287-296. 

Ebersbach G, Heijmenberg M, Kindermann L, Trottenberg T, Wissel J, Poewe W. Interference of rhythmic constraint on gait in healthy subjects and patients with early Parkinson's disease: evidence for impaired locomotor pattern generation in early Parkinson's disease. Mov Disord. Jul 1999;14(4):619-625. 

Ebersbach G, Sojer M, Valldeoriola F, et al. Comparative analysis of gait in Parkinson's disease, cerebellar ataxia and subcortical arteriosclerotic encephalopathy. Brain. Jul 1999;122 ( Pt 7):1349-1355.

Ebersbach G, Stock M, Muller J, Wenning G, Wissel J, Poewe W. Worsening of motor performance in patients with Parkinson's disease following transdermal nicotine administration. Mov Disord. Nov 1999;14(6):1011-1013. 

Foley P, Riederer P. Pathogenesis and preclinical course of Parkinson's disease. J Neural Transm Suppl. 1999;56:31-74. 

Gerlach M, Blum-Degen D, Lan J, Riederer P. Nitric oxide in the pathogenesis of Parkinson's disease. Adv Neurol. 1999;80:239-245. 

Gerlach M, Riederer PF. Time sequences of dopaminergic cell death in Parkinson's disease: indications for neuroprotective studies. Adv Neurol. 1999;80:219-225. 

Gerschlager W, Alesch F, Cunnington R, et al. Bilateral subthalamic nucleus stimulation improves frontal cortex function in Parkinson's disease. An electrophysiological study of the contingent negative variation. Brain. Dec 1999;122 ( Pt 12):2365-2373. 

Gerstenbrand F, Karamat E. Adolf Hitler's Parkinson's disease and an attempt to analyse his personality structure. Eur J Neurol. Mar 1999;6(2):121-127. 

Gilman S, Low PA, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. J Neurol Sci. Feb 1 1999;163(1):94-98. 

Hagell P, Schrag A, Piccini P, et al. Sequential bilateral transplantation in Parkinson's disease: effects of the second graft. Brain. Jun 1999;122 ( Pt 6):1121-1132. 

Hageman G, van der Hoek J, van Hout M, et al. Parkinsonism, pyramidal signs, polyneuropathy, and cognitive decline after long-term occupational solvent exposure. J Neurol. Mar 1999;246(3):198-206. 

Jellinger KA. The role of iron in neurodegeneration: prospects for pharmacotherapy of Parkinson's disease. Drugs Aging. Feb 1999;14(2):115-140. 

Jellinger KA. Is there apoptosis in Lewy body disease? Acta Neuropathol (Berl). Apr 1999;97(4):413-415. 

Jellinger KA. Post mortem studies in Parkinson's disease--is it possible to detect brain areas for specific symptoms? J Neural Transm Suppl. 1999;56:1-29. 

Kienzl E, Jellinger K, Stachelberger H, Linert W. Iron as catalyst for oxidative stress in the pathogenesis of Parkinson's disease? Life Sci. 1999;65(18-19):1973-1976. 

Korczyn AD, Brunt ER, Larsen JP, Nagy Z, Poewe WH, Ruggieri S. A 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease. The 053 Study Group. Neurology. Jul 22 1999;53(2):364-370. 

Kordower JH, Bloch J, Ma SY, et al. Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol. Nov 1999;160(1):1-16. 

Kordower JH, Palfi S, Chen EY, et al. Clinicopathological findings following intraventricular glial-derived neurotrophic factor treatment in a patient with Parkinson's disease. Ann Neurol. Sep 1999;46(3):419-424. 

Kosel S, Hofhaus G, Maassen A, Vieregge P, Graeber MB. Role of mitochondria in Parkinson disease. Biol Chem. Jul-Aug 1999;380(7-8):865-870. 

Kronenberg MF, Menzel HJ, Ebersbach G, et al. Dopamine D4 receptor polymorphism and idiopathic Parkinson's disease. Eur J Hum Genet. Apr 1999;7(3):397-400. 

Liu HW, Kuang YJ, Wu JC, Ma KH, Wang SD, Liu JC. Intrastriatal transplantation of Sertoli cells may improve amphetamine-induced rotation and tyrosine hydroxylase immunoreactivity of the striatum in hemiparkinsonian rats. Brain Res. Aug 14 1999;838(1-2):227-233. 

Mont L, Valentino M, Vacca M, et al. [Analysis of local electrograms and characteristics of the ablation procedure in left-sided accessory pathways that required five or more pulses of radiofrequency]. Rev Esp Cardiol. Aug 1999;52(8):570-576. 

Neef C, van Laar T. Pharmacokinetic-pharmacodynamic relationships of apomorphine in patients with Parkinson's disease. Clin Pharmacokinet. Sep 1999;37(3):257-271. 

Pinter MM. Characteristics of SEP from subthalamic nucleus in human. Electroencephalogr Clin Neurophysiol Suppl. 1999;50:364-372. 

Pinter MM, Alesch F, Murg M, Helscher RJ, Binder H. Apomorphine test: a predictor for motor responsiveness to deep brain stimulation of the subthalamic nucleus. J Neurol. Oct 1999;246(10):907-913. 

Pinter MM, Alesch F, Murg M, Seiwald M, Helscher RJ, Binder H. Deep brain stimulation of the subthalamic nucleus for control of extrapyramidal features in advanced idiopathic parkinson's disease: one year follow-up. J Neural Transm. 1999;106(7-8):693-709. 

Pinter MM, Birk M, Helscher RJ, Binder H. Short-term effect of amantadine sulphate on motor performance and reaction time in patients with idiopathic Parkinson's disease. J Neural Transm. 1999;106(7-8):711-724. 

Pinter MM, Murg M, Alesch F, Freundl B, Helscher RJ, Binder H. Does deep brain stimulation of the nucleus ventralis intermedius affect postural control and locomotion in Parkinson's disease? Mov Disord. Nov 1999;14(6):958-963. 

Pinter MM, Pogarell O, Oertel WH. Efficacy, safety, and tolerance of the non-ergoline dopamine agonist pramipexole in the treatment of advanced Parkinson's disease: a double blind, placebo controlled, randomised, multicentre study. J Neurol Neurosurg Psychiatry. Apr 1999;66(4):436-441. 

Poewe W. The Sydney multicentre study of Parkinson's disease. J Neurol Neurosurg Psychiatry. Sep 1999;67(3):280-281. 

Poewe W. What is new in movement disorders? Wien Klin Wochenschr. Sep 17 1999;111(17):664-671. 

Poewe W. Recent advances in the drug treatment of Parkinson's disease. Curr Opin Neurol. Aug 1999;12(4):411-415. 

Poewe W, Luginger E. Depression in Parkinson's disease: impediments to recognition and treatment options. Neurology. 1999;52(7 Suppl 3):S2-6. 

Pramstaller PP, Falk M, Schoenhuber R, Poewe W. Validation of a mail questionnaire for parkinsonism in two languages (German and Italian). J Neurol. Feb 1999;246(2):79-86. 

Savvateeva EV, Popov AV, Kamyshev NG, et al. Age-dependent changes in memory and mushroom bodies in the Drosophila mutant vermilion deficient in the kynurenine pathway of tryptophan metabolism. Ross Fiziol Zh Im I M Sechenova. Jan 1999;85(1):167-183. 

Schrag A, Schelosky L, Scholz U, Poewe W. Reduction of Parkinsonian signs in patients with Parkinson's disease by dopaminergic versus anticholinergic single-dose challenges. Mov Disord. Mar 1999;14(2):252-255. 

Sian J, Gerlach M, Youdim MB, Riederer P. Parkinson's disease: a major hypokinetic basal ganglia disorder. J Neural Transm. 1999;106(5-6):443-476. 

Siebner HR, Ceballos-Baumann A, Standhardt H, Auer C, Conrad B, Alesch F. Changes in handwriting resulting from bilateral high-frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov Disord. Nov 1999;14(6):964-971.

Ste-Marie L, Vachon L, Bemeur C, Lambert J, Montgomery J. Local striatal infusion of MPP+ does not result in increased hydroxylation after systemic administration of 4-hydroxybenzoate. Free Radic Biol Med. Nov 1999;27(9-10):997-1007. 

Stocchi F, Corazziari E, Carbone A, et al. Urinary and anorectal function evaluation in Parkinson's disease. Adv Neurol. 1999;80:347-351. 

van Laar T, Van der Geest R, Danhof M. Future delivery systems for apomorphine in patients with Parkinson's disease. Adv Neurol. 1999;80:535-544. 

Wenning GK, Bosch S, Luginger E, Wagner M, Poewe W. Effects of long-term, continuous subcutaneous apomorphine infusions on motor complications in advanced Parkinson's disease. Adv Neurol. 1999;80:545-548. 

Wenning GK, Ebersbach G, Verny M, et al. Progression of falls in postmortem-confirmed parkinsonian disorders. Mov Disord. Nov 1999;14(6):947-950. 

Wenning GK, Granata R, Puschban Z, Scherfler C, Poewe W. Neural transplantation in animal models of multiple system atrophy: a review. J Neural Transm Suppl. 1999;55:103-113. 

Wenning GK, Luginger E, Sailer U, Poewe W, Donnemiller E, Riccabona G. Postoperative parkinsonian tremor in a patient with a frontal meningioma. Mov Disord. Mar 1999;14(2):366-368. 

Wullner U, Kornhuber J, Weller M, et al. Cell death and apoptosis regulating proteins in Parkinson's disease--a cautionary note. Acta Neuropathol (Berl). Apr 1999;97(4):408-412. 

Zachhuber C, Leblhuber F, Bancher C, Jellinger K, Drlicek M. [Frontal lobe dementia. Clinical-pathologic case reports]. Fortschr Neurol Psychiatr. Feb 1999;67(2):68-74.

1998

Asenbaum S, Pirker W, Angelberger P, Bencsits G, Pruckmayer M, Brucke T. [123I]beta-CIT and SPECT in essential tremor and Parkinson's disease. J Neural Transm. 1998;105(10-12):1213-1228. 

Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. Neurology. May 1998;50(5 Suppl 5):S46-53. 

Benke T, Bosch S, Andree B. A study of emotional processing in Parkinson's disease. Brain Cogn. Oct 1998;38(1):36-52. 

Bergman H, Feingold A, Nini A, et al. Physiological aspects of information processing in the basal ganglia of normal and parkinsonian primates. Trends Neurosci. Jan 1998;21(1):32-38. 

Debove P, Simon F, Vaylet F, Renard JL, L'Her P. [Pleuropneumopathy caused by bromocriptine in a patient with Parkinson disease. Review of the literature apropos of a new case]. Ann Med Interne (Paris). Apr 1998;149(3):167-171. 

Eder U, Leitner B, Kirchmair R, et al. Levels and proteolytic processing of chromogranin A and B and secretogranin II in cerebrospinal fluid in neurological diseases. J Neural Transm. 1998;105(1):39-51. 

Gerlach M, Koutsilieri E, Riederer P. N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet. Mar 21 1998;351(9106):850-851. 

Gilman S, Low P, Quinn N, et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res. Dec 1998;8(6):359-362. 

Hempel AG, Wagner ML, Maaty MA, Sage JI. Pharmacoeconomic analysis of using Sinemet CR over standard Sinemet in parkinsonian patients with motor fluctuations. Ann Pharmacother. Sep 1998;32(9):878-883. 

Hierholzer J, Cordes M, Venz S, et al. Loss of dopamine-D2 receptor binding sites in Parkinsonian plus syndromes. J Nucl Med. Jun 1998;39(6):954-960. 

Hogl BE, Gomez-Arevalo G, Garcia S, et al. A clinical, pharmacologic, and polysomnographic study of sleep benefit in Parkinson's disease. Neurology. May 1998;50(5):1332-1339. 

Jellinger KA. Commentary on "Neuropathologic evidence that the Lewy body variant of Alzheimer disease represents coexistence of Alzheimer disease and idiopathic Parkinson's disease (1998;57:39-46)". J Neuropathol Exp Neurol. May 1998;57(5):467-468. 

Jellinger KA. [Evaluation of vascular risk factors in patients with Parkinson syndrome]. Nervenarzt. Oct 1998;69(10):929-930. 

Kerschan K, Pankl W, Auff E. [Speech disorders in Parkinson patients]. Wien Klin Wochenschr. Apr 24 1998;110(8):279-286. 

Korczyn AD, Brooks DJ, Brunt ER, Poewe WH, Rascol O, Stocchi F. Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: a 6-month interim report of a 3-year study. 053 Study Group. Mov Disord. Jan 1998;13(1):46-51. 

Litvan I, MacIntyre A, Goetz CG, et al. Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol. Jul 1998;55(7):969-978. 

Moringlane JR, Ceballos-Baumann AO, Alesch F. Long-term effect of electrostimulation of the subthalamic nucleus in bradykinetic-rigid Parkinson's disease. Minim Invasive Neurosurg. Sep 1998;41(3):133-136. 

Munch G, Gerlach M, Sian J, Wong A, Riederer P. Advanced glycation end products in neurodegeneration: more than early markers of oxidative stress? Ann Neurol. Sep 1998;44(3 Suppl 1):S85-88. 

Pfurtscheller G, Pichler-Zalaudek K, Ortmayr B, Diez J, Reisecker F. Postmovement beta synchronization in patients with Parkinson's disease. J Clin Neurophysiol. May 1998;15(3):243-250. 

Poewe W. Adjuncts to levodopa therapy: dopamine agonists. Neurology. Jun 1998;50(6 Suppl 6):S23-26; discussion S44-28. 

Poewe W. Should treatment of Parkinson's disease be started with a dopamine agonist? Neurology. Aug 1998;51(2 Suppl 2):S21-24. 

Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol. Sep 1998;44(3 Suppl 1):S1-9. 

Rascol O, Brooks DJ, Brunt ER, Korczyn AD, Poewe WH, Stocchi F. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group. Mov Disord. Jan 1998;13(1):39-45. 

Riekkinen P, Jr., Kejonen K, Laakso MP, Soininen H, Partanen K, Riekkinen M. Hippocampal atrophy is related to impaired memory, but not frontal functions in non-demented Parkinson's disease patients. Neuroreport. May 11 1998;9(7):1507-1511. 

Rosler M, Retz W, Thome J, Riederer P. Free radicals in Alzheimer's dementia: currently available therapeutic strategies. J Neural Transm Suppl. 1998;54:211-219. 

Schrag AE, Brooks DJ, Brunt E, et al. The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease. Clin Neuropharmacol. May-Jun 1998;21(3):169-175. 

Seiser A, Schwarz S, Aichinger-Steiner MM, Funk G, Schnider P, Brainin M. Parkinsonism and dystonia in central pontine and extrapontine myelinolysis. J Neurol Neurosurg Psychiatry. Jul 1998;65(1):119-121. 

van der Geest R, van Laar T, Kruger PP, et al. Pharmacokinetics, enantiomer interconversion, and metabolism of R-apomorphine in patients with idiopathic Parkinson's disease. Clin Neuropharmacol. May-Jun 1998;21(3):159-168. 

van Laar T, Lammers GJ, Roos RA, Gerritsen JJ, Meinders AE. Antiparkinsonian drugs causing inappropriate antidiuretic hormone secretion. Mov Disord. Jan 1998;13(1):176-178. 

van Laar T, van der Geest R, Danhof M, Bodde HE, Goossens PH, Roos RA. Stepwise intravenous infusion of apomorphine to determine the therapeutic window in patients with Parkinson's disease. Clin Neuropharmacol. May-Jun 1998;21(3):152-158. 

Vogel G. Tau protein mutations confirmed as neuron killers. Science. Jun 5 1998;280(5369):1524-1525. 

Wenning GK, Donnemiller E, Granata R, Riccabona G, Poewe W. 123I-beta-CIT and 123I-IBZM-SPECT scanning in levodopa-naive Parkinson's disease. Mov Disord. May 1998;13(3):438-445. 

Wenning GK, Litvan I, Jankovic J, et al. Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry. Feb 1998;64(2):184-189.

1997

Asenbaum S, Brucke T, Pirker W, et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med. Jan 1997;38(1):1-6. 

Baas H, Beiske AG, Ghika J, et al. Catechol-O-methyltransferase inhibition with tolcapone reduces the "wearing off" phenomenon and levodopa requirements in fluctuating parkinsonian patients. J Neurol Neurosurg Psychiatry. Oct 1997;63(4):421-428. 

Barbato L, Stocchi F, Monge A, et al. The long-duration action of levodopa may be due to a postsynaptic effect. Clin Neuropharmacol. Oct 1997;20(5):394-401. 

Becker T, Becker G, Seufert J, et al. Parkinson's disease and depression: evidence for an alteration of the basal limbic system detected by transcranial sonography. J Neurol Neurosurg Psychiatry. Nov 1997;63(5):590-596. 

Ben-Shlomo Y, Wenning GK, Tison F, Quinn NP. Survival of patients with pathologically proven multiple system atrophy: a meta-analysis. Neurology. Feb 1997;48(2):384-393.

Brucke T, Asenbaum S, Pirker W, et al. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy. J Neural Transm Suppl. 1997;50:9-24. 

Carlsson A, Riederer P, Stern G. Walther Birkmayer--the man behind the name. J Neural Transm. 1997;104(2-3):V-VIII. 

Dhopesh V, Macfadden A, Maany I, Gamble G. Absence of parkinsonism among patients in long-term neuroleptic therapy who abuse cocaine. Psychiatr Serv. Jan 1997;48(1):95-97. 

Diederich NJ, Alesch F. [Neurosurgical methods in treatment of Parkinson disease. Current status]. Nervenarzt. Jun 1997;68(6):466-476. 

Donnemiller E, Heilmann J, Wenning GK, et al. Brain perfusion scintigraphy with 99mTc-HMPAO or 99mTc-ECD and 123I-beta-CIT single-photon emission tomography in dementia of the Alzheimer-type and diffuse Lewy body disease. Eur J Nucl Med. Mar 1997;24(3):320-325. 

Friehs GM, Ojakangas CL, Schrottner O, Ott E, Pendl G. Radiosurgical lesioning of the caudate nucleus as a treatment for parkinsonism: a preliminary report. Neurol Res. Feb 1997;19(1):97-103. 

Gerlach M, Double K, Riederer P, et al. Iron in the Parkinsonian substantia nigra. Mov Disord. Mar 1997;12(2):258-260. 

Gsell W, Strein I, Krause U, Riederer P. Neurochemical abnormalities in Alzheimer's disease and Parkinson's disease--a comparative review. J Neural Transm Suppl. 1997;51:145-159. 

Gu M, Gash MT, Cooper JM, et al. Mitochondrial respiratory chain function in multiple system atrophy. Mov Disord. May 1997;12(3):418-422. 

Holthoff-Detto VA, Kessler J, Herholz K, et al. Functional effects of striatal dysfunction in Parkinson disease. Arch Neurol. Feb 1997;54(2):145-150. 

Horner S, Niederkorn K, Ni XS, et al. [Evaluation of vascular risk factors in patients with Parkinson syndrome]. Nervenarzt. Dec 1997;68(12):967-971. 

Jellinger KA. Morphological substrates of dementia in parkinsonism. A critical update. J Neural Transm Suppl. 1997;51:57-82. 

Klein C, Brown R, Wenning G, Quinn N. The "cold hands sign" in multiple system atrophy. Mov Disord. Jul 1997;12(4):514-518. 

Krauss JK, Regel JP, Droste DW, Orszagh M, Borremans JJ, Vach W. Movement disorders in adult hydrocephalus. Mov Disord. Jan 1997;12(1):53-60. 

Lange KW, Kornhuber J, Riederer P. Dopamine/glutamate interactions in Parkinson's disease. Neurosci Biobehav Rev. Jul 1997;21(4):393-400. 

Lehrner JP, Brucke T, Dal-Bianco P, Gatterer G, Kryspin-Exner I. Olfactory functions in Parkinson's disease and Alzheimer's disease. Chem Senses. Feb 1997;22(1):105-110. 

Litvan I, Campbell G, Mangone CA, et al. Which clinical features differentiate progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) from related disorders? A clinicopathological study. Brain. Jan 1997;120 ( Pt 1):65-74. 

Litvan I, Goetz CG, Jankovic J, et al. What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol. Aug 1997;54(8):937-944. 

Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. Correlation between neuromorphometry in the substantia nigra and clinical features in Parkinson's disease using disector counts. J Neurol Sci. Oct 3 1997;151(1):83-87. 

Pirker W, Asenbaum S, Wenger S, et al. Iodine-123-epidepride-SPECT: studies in Parkinson's disease, multiple system atrophy and Huntington's disease. J Nucl Med. Nov 1997;38(11):1711-1717. 

Rabey JM, Bass H, Bonuccelli U, et al. Evaluation of the Short Parkinson's Evaluation Scale: a new friendly scale for the evaluation of Parkinson's disease in clinical drug trials. Clin Neuropharmacol. Aug 1997;20(4):322-337. 

Rabins PV. Predicting progression of Alzheimer disease. Jama. Jun 25 1997;277(24):1933-1934.

Ruggieri S, De Pandis MF, Bonamartini A, Vacca L, Stocchi F. Low dose of clozapine in the treatment of dopaminergic psychosis in Parkinson's disease. Clin Neuropharmacol. Jun 1997;20(3):204-209. 

Tandberg E, Larsen JP, Aarsland D, Laake K, Cummings JL. Risk factors for depression in Parkinson disease. Arch Neurol. May 1997;54(5):625-630. 

van der Geest R, Kruger P, Gubbens-Stibbe JM, van Laar T, Bodde HE, Danhof M. Assay of R-apomorphine, S-apomorphine, apocodeine, isoapocodeine and their glucuronide and sulfate conjugates in plasma and urine of patients with Parkinson's disease. J Chromatogr B Biomed Sci Appl. Nov 21 1997;702(1-2):131-141. 

van der Geest R, van Laar T, Gubbens-Stibbe JM, Bodde HE, Danhof M. Iontophoretic delivery of apomorphine. II: An in vivo study in patients with Parkinson's disease. Pharm Res. Dec 1997;14(12):1804-1810. 

van Hilten JJ, Wagemans EA, Ghafoerkhan SF, van Laar T. Movement characteristics in Parkinson's disease: determination of dopaminergic responsiveness and threshold. Clin Neuropharmacol. Oct 1997;20(5):402-408. 

Vogel G. Gene discovery offers tentative clues to Parkinson's. Science. Jun 27 1997;276(5321):1973. 

Wenning GK, Jellinger K, Litvan I. Supranuclear gaze palsy and eyelid apraxia in postencephalitic parkinsonism. J Neural Transm. 1997;104(8-9):845-865. 

Wenning GK, Kraft E, Beck R, et al. Cerebellar presentation of multiple system atrophy. Mov Disord. Jan 1997;12(1):115-117. 

Wenning GK, Odin P, Morrish P, et al. Short- and long-term survival and function of unilateral intrastriatal dopaminergic grafts in Parkinson's disease. Ann Neurol. Jul 1997;42(1):95-107. 

Wenning GK, Pramstaller PP, Ransmayr G, Poewe W. [Atypical Parkinson syndrome]. Nervenarzt. Feb 1997;68(2):102-115. 

Wenning GK, Tison F, Ben Shlomo Y, Daniel SE, Quinn NP. Multiple system atrophy: a review of 203 pathologically proven cases. Mov Disord. Mar 1997;12(2):133-147. 

Xie T, Ho SL, Li LS, Ma OC. G/A1947 polymorphism in catechol-O-methyltransferase (COMT) gene in Parkinson's disease. Mov Disord. May 1997;12(3):426-427. 

Youdim MB, Riederer P. Understanding Parkinson's disease. Sci Am. Jan 1997;276(1):52-59.

1996

Aichner F, Wagner M, Kremser C, Felber S. MR-imaging of non-Alzheimer's dementia. J Neural Transm Suppl. 1996;47:143-153. 

Aizawa Y, Ma ML. [Catheter ablation for therapy of patients with arrhythmia]. Nippon Rinsho. Aug 1996;54(8):2159-2164. 

Cordes M, Hierholzer J, Schelosky L, et al. Iodine-123-iodo-lisuride SPECT in Parkinson's disease. J Nucl Med. Jan 1996;37(1):22-25. 

Ebersbach G, Trottenberg T, Hattig H, Schelosky L, Schrag A, Poewe W. Directional bias of initial visual exploration. A symptom of neglect in Parkinson's disease. Brain. Feb 1996;119 ( Pt 1):79-87. 

Egensperger R, Bancher C, Kosel S, Jellinger K, Mehraein P, Graeber MB. The apolipoprotein E epsilon 4 allele in Parkinson's disease with Alzheimer lesions. Biochem Biophys Res Commun. Jul 16 1996;224(2):484-486. 

Gerlach M, Desser H, Youdim MB, Riederer P. New horizons in molecular mechanisms underlying Parkinson's disease and in our understanding of the neuroprotective effects of selegiline. J Neural Transm Suppl. 1996;48:7-21. 

Gerlach M, Gsell W, Kornhuber J, et al. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res. Nov 25 1996;741(1-2):142-152. 

Gerlach M, Riederer P. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. J Neural Transm. 1996;103(8-9):987-1041. 

Gerlach M, Riederer P. [Pathogenesis and neuroprotective therapy trial in chronic degenerative diseases. Status of antioxidants]. Med Klin (Munich). Mar 15 1996;91(3):163-170. 

Gerlach M, Riederer P, Vogt H. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. "On treatment" rather than intention to treat analysis should have been used. Bmj. Mar 16 1996;312(7032):704; author reply 704-705. 

Gerlach M, Riederer P, Youdim MB. Molecular mechanisms for neurodegeneration. Synergism between reactive oxygen species, calcium, and excitotoxic amino acids. Adv Neurol. 1996;69:177-194. 

Hierholzer J, Castelli L, Cordes M, Schelosky L, Poewe W, Felix R. [Cerebral SPECT with iodine-123 IBZM in patients with extrapyramidal system disorders: the evaluation of its sensitivity in therapy with dopaminergic drugs]. Radiol Med (Torino). Mar 1996;91(3):207-210. 

Hierholzer J, Schrag A, Cordes M, et al. [Magnetic resonance tomography in patients with Parkinson's disease and Parkinson-plus syndromes]. Rofo. Jul 1996;165(1):43-51. 

Inzelberg R, Nisipeanu P, Rabey JM, et al. Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. Neurology. Sep 1996;47(3):785-788. 

Jellinger KA. The neuropathologic diagnosis of secondary parkinsonian syndromes. Adv Neurol. 1996;69:293-303. 

Jellinger KA. Effect of adding selegeline to levodopa in early, mild Parkinson's disease. Causes of death need confirmation. Bmj. Mar 16 1996;312(7032):704-705. 

Jellinger KA. Parkinsonism due to Binswanger's subcortical arteriosclerotic encephalopathy. Mov Disord. Jul 1996;11(4):461-462. 

Jendroska K, Lees AJ, Poewe W, Daniel SE. Amyloid beta-peptide and the dementia of Parkinson's disease. Mov Disord. Nov 1996;11(6):647-653. 

Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res. Nov 25 1996;741(1-2):185-196. 

Laakso MP, Partanen K, Riekkinen P, et al. Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: An MRI study. Neurology. Mar 1996;46(3):678-681. 

Linert W, Herlinger E, Jameson RF, Kienzl E, Jellinger K, Youdim MB. Dopamine, 6-hydroxydopamine, iron, and dioxygen--their mutual interactions and possible implication in the development of Parkinson's disease. Biochim Biophys Acta. Aug 23 1996;1316(3):160-168. 

Litvan I, DeLeo JM, Hauw JJ, et al. What can artificial neural networks teach us about neurodegenerative disorders with extrapyramidal features? Brain. Jun 1996;119 ( Pt 3):831-839. 

Litvan I, Hauw JJ, Bartko JJ, et al. Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol. Jan 1996;55(1):97-105. 

Litvan I, Mangone CA, McKee A, et al. Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry. Jun 1996;60(6):615-620. 

Ma SY, Rinne JO, Collan Y, Roytta M, Rinne UK. A quantitative morphometrical study of neuron degeneration in the substantia nigra in Parkinson's disease. J Neurol Sci. Sep 1 1996;140(1-2):40-45. 

Maany I. Adverse interaction of tacrine and haloperidol. Am J Psychiatry. Nov 1996;153(11):1504. 

McKeith IG, Galasko D, Kosaka K, et al. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the consortium on DLB international workshop. Neurology. Nov 1996;47(5):1113-1124. 

Mogi M, Harada M, Kondo T, et al. bcl-2 protein is increased in the brain from parkinsonian patients. Neurosci Lett. Sep 6 1996;215(2):137-139. 

Mogi M, Harada M, Kondo T, et al. The soluble form of Fas molecule is elevated in parkinsonian brain tissues. Neurosci Lett. Dec 20 1996;220(3):195-198. 

Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T. Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication. J Neural Transm. 1996;103(8-9):1077-1081. 

Neufeld MY, Rabey JM, Orlov E, Korczyn AD. Electroencephalographic findings with low-dose clozapine treatment in psychotic Parkinsonian patients. Clin Neuropharmacol. Feb 1996;19(1):81-86.

Poewe WH, Wenning GK. The natural history of Parkinson's disease. Neurology. Dec 1996;47(6 Suppl 3):S146-152. 

Przuntek H, Welzel D, Gerlach M, et al. Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study. J Neural Transm. 1996;103(6):699-715. 

Rabey JM, Neufeld MY, Treves TA, Sifris P, Korczyn AD. Cognitive effects of scopolamine in dementia. J Neural Transm. 1996;103(7):873-881. 

Raz A, Feingold A, Zelanskaya V, Vaadia E, Bergman H. Neuronal synchronization of tonically active neurons in the striatum of normal and parkinsonian primates. J Neurophysiol. Sep 1996;76(3):2083-2088. 

Ruggieri S, Fabbrini G, Bramante L, et al. An open study with reversible MAO-A inhibitors in complicated Parkinson's disease. Adv Neurol. 1996;69:595-598. 

Stocchi F, Barbato L, Bramante L, Nordera G, Vacca L, Ruggieri S. Fluctuating parkinsonism: a pilot study of single afternoon dose of levodopa methyl ester. J Neurol. May 1996;243(5):377-380. 

Stocchi F, Bonamartini A, Vacca L, Ruggieri S. Motor fluctuations in levodopa treatment: clinical pharmacology. Eur Neurol. 1996;36 Suppl 1:38-42. 

Tison F, Wenning GK, Volonte MA, Poewe WR, Henry P, Quinn NP. Pain in multiple system atrophy. J Neurol. Feb 1996;243(2):153-156. 

van Laar T, Neef C, Danhof M, Roon KI, Roos RA. A new sublingual formulation of apomorphine in the treatment of patients with Parkinson's disease. Mov Disord. Nov 1996;11(6):633-638. 

Wenning GK, Quinn NP, Daniel SE, Garratt H, Marsden CD. Facial dystonia in pathologically proven multiple system atrophy: a video report. Mov Disord. Jan 1996;11(1):107-109. 

Wenning GK, Tison F, Elliott L, Quinn NP, Daniel SE. Olivopontocerebellar pathology in multiple system atrophy. Mov Disord. Mar 1996;11(2):157-162.

1995

Alesch F. [Neurosurgical methods in Parkinson disease]. Wien Med Wochenschr. 1995;145(13):305-309. 

Alesch F, Koos WT. Computer-assisted multidimensional atlas for functional stereotaxy. Acta Neurochir (Wien). 1995;133(3-4):153-156. 

Alesch F, Pinter MM, Helscher RJ, Fertl L, Benabid AL, Koos WT. Stimulation of the ventral intermediate thalamic nucleus in tremor dominated Parkinson's disease and essential tremor. Acta Neurochir (Wien). 1995;136(1-2):75-81. 

Auff E, Fertl E, Schnider P. [Parkinson disease and neurologic rehabilitation]. Wien Med Wochenschr. 1995;145(13):302-305. 

Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K. Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography. Neurology. Jan 1995;45(1):182-184. 

Blum-Degen D, Frolich L, Hoyer S, Riederer P. Altered regulation of brain glucose metabolism as a cause of neurodegenerative disorders? J Neural Transm Suppl. 1995;46:139-147. 

Blum-Degen D, Muller T, Kuhn W, Gerlach M, Przuntek H, Riederer P. Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients. Neurosci Lett. Dec 29 1995;202(1-2):17-20. 

Brucke T, Wober C, Podreka I, et al. D2 receptor blockade by flunarizine and cinnarizine explains extrapyramidal side effects. A SPECT study. J Cereb Blood Flow Metab. May 1995;15(3):513-518. 

Davie CA, Wenning GK, Barker GJ, et al. Differentiation of multiple system atrophy from idiopathic Parkinson's disease using proton magnetic resonance spectroscopy. Ann Neurol. Feb 1995;37(2):204-210. 

Eichhorn TE, Schrag A, Trenkwalder C, et al. [Effectiveness of slow release L-DOPA/benserazide in treatment of end-of-dose akinesia in Parkinson disease]. Nervenarzt. Dec 1995;66(12):933-941. 

Friehs GM, Ojakangas CL, Pachatz P, Schrottner O, Ott E, Pendl G. Thalamotomy and caudatotomy with the Gamma Knife as a treatment for parkinsonism with a comment on lesion sizes. Stereotact Funct Neurosurg. 1995;64 Suppl 1:209-221. 

Gerlach M, Riederer P, Youdim MB. Neuroprotective therapeutic strategies. Comparison of experimental and clinical results. Biochem Pharmacol. Jun 29 1995;50(1):1-16. 

Gonska BD, Rab J. [Acute therapy of tachycardic arrhythmias. 2: Supraventricular tachycardia--atrioventricular tachycardia (WPW syndrome)]. Fortschr Med. Mar 10 1995;113(7):87-89. 

Hierholzer J, Cordes M, Schelosky L, et al. [Brain SPECT with 123I-lisuride in patients with Parkinson's disease and controls]. Nuklearmedizin. Aug 1995;34(4):141-145. 

Horowski R, Horowski L, Vogel S, Poewe W, Kielhorn FW. An essay on Wilhelm von Humboldt and the shaking palsy: first comprehensive description of Parkinson's disease by a patient. Neurology. Mar 1995;45(3 Pt 1):565-568. 

Inzelberg R, Nisipeanu P, Rabey MJ, Korczyn AD. Long-term tolerability and efficacy of cabergoline, a new long-acting dopamine agonist, in Parkinson's disease. Mov Disord. Sep 1995;10(5):604-607. 

Jellinger K, Linert L, Kienzl E, Herlinger E, Youdim MB. Chemical evidence for 6-hydroxydopamine to be an endogenous toxic factor in the pathogenesis of Parkinson's disease. J Neural Transm Suppl. 1995;46:297-314. 

Jimenez-Jimenez FJ, Molina JA, Aguilar MV, et al. Serum and urinary manganese levels in patients with Parkinson's disease. Acta Neurol Scand. May 1995;91(5):317-320. 

Kienzl E, Puchinger L, Jellinger K, Linert W, Stachelberger H, Jameson RF. The role of transition metals in the pathogenesis of Parkinson's disease. J Neurol Sci. Dec 1995;134 Suppl:69-78. 

Koppi S, Kaufmann C, Barolin GS. [Outcome-oriented Barolin Neurorehabilitation Scale: 476 cases over 6 years--multi-nodal statistical correlation of neurorehabilitation groups in diagnosis, prognosis and outcome]. Wien Med Wochenschr. 1995;145(19-20):555-567. 

Kornhuber J, Quack G, Danysz W, et al. Therapeutic brain concentration of the NMDA receptor antagonist amantadine. Neuropharmacology. Jul 1995;34(7):713-721. 

Lehrner J, Brucke T, Kryspin-Exner I, Asenbaum S, Podreka I. Impaired olfactory function in Parkinson's disease. Lancet. Apr 22 1995;345(8956):1054-1055. 

Ma C, Liu X, Hu D, et al. Transseptal methods for percutaneous balloon valvoplasty simultaneously with radiofrequency catheter ablation. Chin Med J (Engl). Dec 1995;108(12):883-886. 

Ma SY, Collan Y, Roytta M, Rinne JO, Rinne UK. Cell counts in the substantia nigra: a comparison of single section counts and disector counts in patients with Parkinson's disease and in controls. Neuropathol Appl Neurobiol. Feb 1995;21(1):10-17. 

Ma SY, Roytta M, Rinne JO, Collan Y, Rinne UK. Single section and disector counts in evaluating neuronal loss from the substantia nigra in patients with Parkinson's disease. Neuropathol Appl Neurobiol. Aug 1995;21(4):341-343. 

Magalhaes M, Wenning GK, Daniel SE, Quinn NP. Autonomic dysfunction in pathologically confirmed multiple system atrophy and idiopathic Parkinson's disease--a retrospective comparison. Acta Neurol Scand. Feb 1995;91(2):98-102. 

Manfredi M, Stocchi F, Vacca L. Differential diagnosis of parkinsonism. J Neural Transm Suppl. 1995;45:1-9. 

Mogi M, Harada M, Kondo T, Narabayashi H, Riederer P, Nagatsu T. Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease. Neurosci Lett. Jun 30 1995;193(2):129-132. 

Mogi M, Harada M, Kondo T, Riederer P, Nagatsu T. Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1995;9(1):87-92. 

Plante-Bordeneuve V, Bandmann O, Wenning G, Quinn NP, Daniel SE, Harding AE. CYP2D6-debrisoquine hydroxylase gene polymorphism in multiple system atrophy. Mov Disord. May 1995;10(3):277-278. 

Rabey JM. Second generation of dopamine agonists: pros and cons. J Neural Transm Suppl. 1995;45:213-224. 

Rabey JM, Treves TA, Neufeld MY, Orlov E, Korczyn AD. Low-dose clozapine in the treatment of levodopa-induced mental disturbances in Parkinson's disease. Neurology. Mar 1995;45(3 Pt 1):432-434.

Reichmann H, Janetzky B, Riederer P. Iron-dependent enzymes in Parkinson's disease. J Neural Transm Suppl. 1995;46:157-164. 

Sontag KH, Heim C, Sontag TA, et al. Long-term behavioural effects of TaClo (1-trichloromethyl-1,2,3,4-tetrahydro-beta-carboline) after subchronic treatment in rats. J Neural Transm Suppl. 1995;46:283-289. 

Tison F, Wenning GK, Daniel SE, Quinn NP. [Multiple system atrophy with Lewy bodies]. Rev Neurol (Paris). Jun-Jul 1995;151(6-7):398-403. 

van Laar T, Jansen EN, Neef C, Danhof M, Roos RA. Pharmacokinetics and clinical efficacy of rectal apomorphine in patients with Parkinson's disease: a study of five different suppositories. Mov Disord. Jul 1995;10(4):433-439. 

Volc D. [Clinical manifestations of Parkinson disease]. Wien Med Wochenschr. 1995;145(13):290-294. 

Wenning GK, Ben-Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinicopathological study of 35 cases of multiple system atrophy. J Neurol Neurosurg Psychiatry. Feb 1995;58(2):160-166. 

Wenning GK, O'Connell MT, Patsalos PN, Quinn NP. A clinical and pharmacokinetic case study of an interaction of levodopa and antituberculous therapy in Parkinson's disease. Mov Disord. Sep 1995;10(5):664-667. 

Wenning GK, Shephard B, Hawkes C, Petruckevitch A, Lees A, Quinn N. Olfactory function in atypical parkinsonian syndromes. Acta Neurol Scand. Apr 1995;91(4):247-250. 

Wesemann W, Solbach M, Nafe R, et al. Effect of lazaroid U-74389G on iron-induced reduction of striatal dopamine metabolism. J Neural Transm Suppl. 1995;46:175-182.

1994

Albrecht NN, Netherton SD, Elias JW, Albrecht JW, Whitfield KE, Hutton JT. Assessment of intellectual functioning of patients with Parkinson's disease using the Satz-Mogel (1962) short form of the Wechsler

Adult Intelligence Scale. Exp Aging Res. Apr-Jun 1994;20(2):155-172. 

Ben-Shlomo Y, Wenning G. Incidental Lewy body disease. Lancet. Nov 26 1994;344(8935):1503. 

Bockelmann R, Wolf G, Ransmayr G, Riederer P. NADPH-diaphorase/nitric oxide synthase containing neurons in normal and Parkinson's disease putamen. J Neural Transm Park Dis Dement Sect. 1994;7(2):115-121. 

Braak H, Braak E, Yilmazer D, et al. Amygdala pathology in Parkinson's disease. Acta Neuropathol (Berl). 1994;88(6):493-500. 

Cabrera-Valdivia F, Jimenez-Jimenez FJ, Molina JA, et al. Peripheral iron metabolism in patients with Parkinson's disease. J Neurol Sci. Aug 1994;125(1):82-86. 

Cordes M, Poewe W. [Presynaptic nigrostriatal function in Parkinson disease and Parkinson-plus syndromes. Comparative studies using positron emission tomography with L-6-(18F)fluorodopa]. Nervenarzt. Oct 1994;65(10):696-699. 

Ebersbach G, Hattig H, Schelosky L, Wissel J, Poewe W. Perseverative motor behaviour in Parkinson's disease. Neuropsychologia. Jul 1994;32(7):799-804. 

Gerlach M, Ben-Shachar D, Riederer P, Youdim MB. Altered brain metabolism of iron as a cause of neurodegenerative diseases? J Neurochem. Sep 1994;63(3):793-807. 

Gerlach M, Youdim MB, Riederer P. Is selegiline neuroprotective in Parkinson's disease? J Neural Transm Suppl. 1994;41:177-188. 

Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology. Nov 1994;44(11):2015-2019. 

Hofstee DJ, Neef C, van Laar T, Jansen EN. Pharmacokinetics of apomorphine in Parkinson's disease: plasma and cerebrospinal fluid levels in relation to motor responses. Clin Neuropharmacol. Feb 1994;17(1):45-52. 

Holthoff VA, Vieregge P, Kessler J, et al. Discordant twins with Parkinson's disease: positron emission tomography and early signs of impaired cognitive circuits. Ann Neurol. Aug 1994;36(2):176-182. 

Ichinose H, Ohye T, Fujita K, et al. Quantification of mRNA of tyrosine hydroxylase and aromatic L-amino acid decarboxylase in the substantia nigra in Parkinson's disease and schizophrenia. J Neural Transm Park Dis Dement Sect. 1994;8(1-2):149-158. 

Janetzky B, Hauck S, Youdim MB, et al. Unaltered aconitase activity, but decreased complex I activity in substantia nigra pars compacta of patients with Parkinson's disease. Neurosci Lett. Mar 14 1994;169(1-2):126-128. 

Jendroska K, Hoffmann O, Schelosky L, Lees AJ, Poewe W, Daniel SE. Absence of disease related prion protein in neurodegenerative disorders presenting with Parkinson's syndrome. J Neurol Neurosurg Psychiatry. Oct 1994;57(10):1249-1251. 

Lange KW, Rausch WD, Gsell W, Naumann M, Oestreicher E, Riederer P. Neuroprotection by dopamine agonists. J Neural Transm Suppl. 1994;43:183-201. 

Lange KW, Riederer P. Glutamatergic drugs in Parkinson's disease. Life Sci. 1994;55(25-26):2067-2075. 

Lange KW, Riederer P, Youdim MB. Biochemical actions of l-deprenyl (selegiline). Clin Pharmacol Ther. Dec 1994;56(6 Pt 2):734-741. 

Mogi M, Harada M, Kondo T, et al. Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients. Neurosci Lett. Oct 24 1994;180(2):147-150. 

Mogi M, Harada M, Riederer P, Narabayashi H, Fujita K, Nagatsu T. Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients. Neurosci Lett. Jan 3 1994;165(1-2):208-210. 

Molina JA, Jimenez-Jimenez FJ, Navarro JA, et al. Plasma levels of nitrates in patients with Parkinson's disease. J Neurol Sci. Dec 1 1994;127(1):87-89. 

Muller C, Wenger S, Fertl L, Auff E. Initiation of visual-guided random saccades and remembered saccades in parkinsonian patients with severe motor-fluctuations. J Neural Transm Park Dis Dement Sect. 1994;7(2):101-108. 

Neef C, Jelliffe RW, van Laar T, Loohuis T, Essink AW, Janssen EN. Comparison of two software programs to be used for the calculation of population pharmacokinetic parameters. Int J Biomed Comput. Jun 1994;36(1-2):143-150. 

Poewe WH. Clinical aspects of motor fluctuations in Parkinson's disease. Neurology. Jul 1994;44(7 Suppl 6):S6-9. 

Rabey JM, Nissipeanu P, Inzelberg R, Korczyn AD. Beneficial effect of cabergoline, new long-lasting D2 agonist in the treatment of Parkinson's disease. Clin Neuropharmacol. Jun 1994;17(3):286-293.

Reichmann H, Janetzky B, Bischof F, et al. Unaltered respiratory chain enzyme activity and mitochondrial DNA in skeletal muscle from patients with idiopathic Parkinson's syndrome. Eur Neurol. 1994;34(5):263-267. 

Rodriguez M, Lera G, Vaamonde J, Luquin MR, Obeso JA. Motor response to apomorphine and levodopa in asymmetric Parkinson's disease. J Neurol Neurosurg Psychiatry. May 1994;57(5):562-566. 

Roos RA, van Laar T, van Hilten JJ. [Limited value of the apomorphine test in Parkinson disease]. Ned Tijdschr Geneeskd. Jul 2 1994;138(27):1374-1376. 

Schelosky L, Poewe W. [Life expectancy and disability in Parkinson disease]. Versicherungsmedizin. Aug 1 1994;46(4):119-122. 

Wenning G, Quinn N. Are Lewy bodies non-specific epiphenomena of nigral damage? Mov Disord. May 1994;9(3):378-379. 

Wenning GK, Ben Shlomo Y, Magalhaes M, Daniel SE, Quinn NP. Clinical features and natural history of multiple system atrophy. An analysis of 100 cases. Brain. Aug 1994;117 ( Pt 4):835-845. 

Wenning GK, Jager R, Kendall B, Kingsley D, Daniel SE, Quinn NP. Is cranial computerized tomography useful in the diagnosis of multiple system atrophy? Mov Disord. May 1994;9(3):333-336. 

Wenning GK, Quinn N, Magalhaes M, Mathias C, Daniel SE. "Minimal change" multiple system atrophy. Mov Disord. Mar 1994;9(2):161-166. 

Wesemann W, Blaschke S, Solbach M, Grote C, Clement HW, Riederer P. Intranigral injected iron progressively reduces striatal dopamine metabolism. J Neural Transm Park Dis Dement Sect. 1994;8(3):209-214. 

Youdim MB, Ben-Shachar D, Riederer P. The enigma of neuromelanin in Parkinson's disease substantia nigra. J Neural Transm Suppl. 1994;43:113-122. 

Youdim MB, Lavie L, Riederer P. Oxygen free radicals and neurodegeneration in Parkinson's disease: a role for nitric oxide. Ann N Y Acad Sci. Nov 17 1994;738:64-68.

1993

Alvarez-Gomez MJ, Vaamonde J, Narbona J, et al. Parkinsonian syndrome in childhood after sodium valproate administration. Clin Neuropharmacol. Oct 1993;16(5):451-455. 

Arnold G, Bondy B, Bandmann O, et al. 3H-spiperone binding to lymphocytes fails in the differential diagnosis of de novo Parkinson syndromes. J Neural Transm Park Dis Dement Sect. 1993;5(2):107-116. 

Bancher C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett. Nov 12 1993;162(1-2):179-182. 

Birkmayer JG, Vrecko C, Volc D, Birkmayer W. Nicotinamide adenine dinucleotide (NADH)--a new therapeutic approach to Parkinson's disease. Comparison of oral and parenteral application. Acta Neurol Scand Suppl. 1993;146:32-35. 

Brucke T, Kornhuber J, Angelberger P, Asenbaum S, Frassine H, Podreka I. SPECT imaging of dopamine and serotonin transporters with [123I]beta-CIT. Binding kinetics in the human brain. J Neural Transm Gen Sect. 1993;94(2):137-146. 

Brucke T, Wenger S, Asenbaum S, et al. Dopamine D2 receptor imaging and measurement with SPECT. Adv Neurol. 1993;60:494-500. 

Cordes M, Hierholzer J, Schelosky L, et al. IBZM-SPECT imaging in Parkinson's disease. Quantification of binding ratios from sequential SPECT measurements in patients and controls. Adv Neurol. 1993;60:525-528. 

Davie CA, Wenning GK, Barker GJ, Brennan A, Quinn N, Miller DH. MRS to differentiate multiple system atrophy from idiopathic Parkinson's disease. Lancet. Sep 11 1993;342(8872):681-682. 

Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in de novo parkinsonian patients: evidence for phase-shifting properties of l-dopa. J Neural Transm Park Dis Dement Sect. 1993;5(3):227-234. 

Fertl E, Doppelbauer A, Auff E. Physical activity and sports in patients suffering from Parkinson's disease in comparison with healthy seniors. J Neural Transm Park Dis Dement Sect. 1993;5(2):157-161. 

Hartmann J, Kunig G, Riederer P. Involvement of transmitter systems in neuropsychiatric diseases. Acta Neurol Scand Suppl. 1993;146:18-21. 

Helscher RJ, Pinter MM. Speed and power of higher cerebral functions in parkinsonian patients. J Neural Transm Park Dis Dement Sect. 1993;5(1):35-44. 

Hierholzer J, Cordes M, Schelosky L, et al. [The differential diagnosis of Parkinson diseases--123I-IBZM-SPECT vs. the apomorphine test]. Rofo. Jul 1993;159(1):86-90. 

Jellinger K, Kienzl E, Rumpelmair G, et al. Neuromelanin and nigrostriatal dopamine neuron degeneration. J Neurochem. May 1993;60(5):1976-1977. 

Jellinger KA, Kienzl E, Rumpelmaier G, et al. Iron and ferritin in substantia nigra in Parkinson's disease. Adv Neurol. 1993;60:267-272. 

Jellinger KA, Lantos PL, Mehraein P. Pathological assessment of movement disorders: requirements for documentation in brain banks. J Neural Transm Suppl. 1993;39:173-184. 

Kornhuber J, Riederer P. N-methyl-D-aspartate (NMDA) antagonists in Parkinson's disease. J Neurol Neurosurg Psychiatry. Apr 1993;56(4):427. 

Kornhuber J, Weller M, Riederer P. Glutamate receptor antagonists for neuroleptic malignant syndrome and akinetic hyperthermic parkinsonian crisis. J Neural Transm Park Dis Dement Sect. 1993;6(1):63-72. 

Kreczy-Kleedorfer B, Wagner M, Bosch S, Poewe W. [Long-term results of continuous subcutaneous apomorphine pump therapy in patients with advanced Parkinson disease]. Nervenarzt. Apr 1993;64(4):221-225. 

Kusaba H, Kudo J, Kuruma T, et al. [Interferon therapy after ablation of Kent bundle for a patient with chronic hepatitis type B complicated with WPW syndrome]. Fukuoka Igaku Zasshi. Jun 1993;84(6):330-333. 

Larumbe R, Vaamonde J, Artieda J, Zubieta JL, Obeso JA. Reflex blepharospasm associated with bilateral basal ganglia lesion. Mov Disord. Apr 1993;8(2):198-200. 

Lera G, Vaamonde J, Rodriguez M, Obeso JA. Cabergoline in Parkinson's disease: long-term follow-up. Neurology. Dec 1993;43(12):2587-2590. 

Pinter MM, Helscher RJ. Therapeutic effect of clozapine in psychotic decompensation in idiopathic Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1993;5(2):135-146. 

Pinter MM, Helscher RJ, Sattler AP. [Apomorphine test in Parkinson disease--dose and corresponding parameters]. Wien Klin Wochenschr. 1993;105(16):472-475. 

Poewe W. Clinical features, diagnosis, and imaging of parkinsonian syndromes. Curr Opin Neurol Neurosurg. Jun 1993;6(3):333-338. 

Poewe W. Clinical and pathophysiologic aspects of late levodopa failure. Neurology. Dec 1993;43(12 Suppl 6):S28-30. 

Poewe W, Kleedorfer B, Wagner M, Bosch S, Schelosky L. Continuous subcutaneous apomorphine infusions for fluctuating Parkinson's disease. Long-term follow-up in 18 patients. Adv Neurol. 1993;60:656-659. 

Przedborski S, Goldman S, Levivier M, et al. Brain glucose metabolism and dopamine D2 receptor analysis in a patient with hemiparkinsonism-hemiatrophy syndrome. Mov Disord. Jul 1993;8(3):391-395. 

Rabey JM, Shabtai H, Graff E, Oberman Z. [3H] dopamine uptake by platelet storage granules in Parkinson's disease. Life Sci. 1993;53(23):1753-1759. 

Rabey JM, Vered Y, Shabtai H, Graff E, Harsat A, Korczyn AD. Broad bean (Vicia faba) consumption and Parkinson's disease. Adv Neurol. 1993;60:681-684. 

Ransmayr G, Kunig G, Neubauer M, Wagner M, Bosch S, Kreczy-Kleedorfer B. Is the decreasing responsiveness of axial motor symptoms to L-dopa in elderly parkinsonian patients related to age-associated nonparkinsonian pathologies? Adv Neurol. 1993;60:685-689. 

Reichmann H, Janetzky B, Klinge M, Riederer P. [Parkinson disease--a mitochondrial myopathy?]. Nervenarzt. Apr 1993;64(4):215-220. 

Reichmann H, Lestienne P, Jellinger K, Riederer P. Parkinson's disease and the electron transport chain in postmortem brain. Adv Neurol. 1993;60:297-299. 

Riederer P, Lange KW, Youdim MB. Recent advances in pharmacological therapy of Parkinson's disease. Adv Neurol. 1993;60:626-635. 

Schelosky L, Hierholzer J, Wissel J, Cordes M, Poewe W. Correlation of clinical response in apomorphine test with D2-receptor status as demonstrated by 123I IBZM-SPECT. Mov Disord. Oct 1993;8(4):453-458. 

Schelosky L, Poewe W. Current strategies in the drug treatment of advanced Parkinson's disease--new modes of dopamine substitution. Acta Neurol Scand Suppl. 1993;146:46-49. 

Vaamonde J, Legarda I, Jimenez-Jimenez J, Zubieta JL, Obeso JA. Levodopa-responsive parkinsonism associated with basal ganglia calcification and primary hypoparathyroidism. Mov Disord. Jul 1993;8(3):398-400. 

van Laar T, Jansen EN, Essink AW, Neef C, Oosterloo S, Roos RA. A double-blind study of the efficacy of apomorphine and its assessment in 'off'-periods in Parkinson's disease. Clin Neurol Neurosurg. Sep 1993;95(3):231-235. 

Wenning GK, Wagner S, Daniel S, Quinn NP. Multiple system atrophy: sporadic or familial? Lancet. Sep 11 1993;342(8872):681. 

Youdim MB, Ben-Shachar D, Eshel G, Finberg JP, Riederer P. The neurotoxicity of iron and nitric oxide. Relevance to the etiology of Parkinson's disease. Adv Neurol. 1993;60:259-266. 

Youdim MB, Ben-Shachar D, Riederer P. The possible role of iron in the etiopathology of Parkinson's disease. Mov Disord. 1993;8(1):1-12. 

Youdim MB, Riederer P. The role of iron in senescence of dopaminergic neurons in Parkinson's disease. J Neural Transm Suppl. 1993;40:57-67. 

Youdim MB, Riederer P. The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease. Mov Disord. 1993;8 Suppl 1:S8-13. 

Youdim MB, Riederer P. Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition. J Neural Transm Gen Sect. 1993;91(2-3):181-195. 

Zeitlhofer J, Tribl G, Saletu B. [Sleep disorders in neurology: hyposomnia]. Wien Klin Wochenschr. 1993;105(2):37-41.

1992

Baran H, Jellinger K. Human brain phenolsulfotransferase. Regional distribution in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1992;4:267-276. 

Ben-Shachar D, Eshel G, Riederer P, Youdim MB. Role of iron and iron chelation in dopaminergic-induced neurodegeneration: implication for Parkinson's disease. Ann Neurol. 1992;32 Suppl:S105-110. 

Grandas F, Luquin MR, Rodriguez M, Vaamonde J, Lera G, Obeso JA. [Motor fluctuations in Parkinson disease: risk factors]. Neurologia. May 1992;7(5):89-93. 

Haissaguerre M, Fischer B, Labbe T, et al. Frequency of recurrent atrial fibrillation after catheter ablation of overt accessory pathways. Am J Cardiol. Feb 15 1992;69(5):493-497. 

Hierholzer J, Cordes M, Schelosky L, et al. [The determination of cerebral dopamine (D2) receptor density by using 123I-IBZM-SPECT in Parkinson disease patients]. Rofo. Oct 1992;157(4):390-398. 

Jellinger K. Juvenile-onset parkinsonism: same patient reported twice. Neurology. May 1992;42(5):1124-1125. 

Jellinger K, Kienzl E, Rumpelmair G, et al. Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis. J Neurochem. Sep 1992;59(3):1168-1171. 

Jellinger KA, Paulus W. Clinico-pathological correlations in Parkinson's disease. Clin Neurol Neurosurg. 1992;94 Suppl:S86-88. 

Karbe H, Holthoff V, Huber M, et al. Positron emission tomography in degenerative disorders of the dopaminergic system. J Neural Transm Park Dis Dement Sect. 1992;4(2):121-130. 

Kleedorfer B, Poewe W. Comparative efficacy of two oral sustained-release preparations of L-dopa in fluctuating Parkinson's disease. Preliminary findings in 20 patients. J Neural Transm Park Dis Dement Sect. 1992;4(2):173-178. 

Lange KW, Youdim MB, Riederer P. Neurotoxicity and neuroprotection in Parkinson's disease. J Neural Transm Suppl. 1992;38:27-44. 

Luquin MR, Scipioni O, Vaamonde J, Gershanik O, Obeso JA. Levodopa-induced dyskinesias in Parkinson's disease: clinical and pharmacological classification. Mov Disord. 1992;7(2):117-124. 

Obeso JA, Luquin MR, Grandas F, Vaamonde J, Laguna J, Martinez-Lage JM. Motor response to repeated dopaminergic stimulation in Parkinson's disease. Clin Neuropharmacol. Feb 1992;15(1):75-79. 

Pinter MM, Helscher RJ, Nasel CO, Riedl E, Schnaberth G. Quantification of motor deficit in Parkinson's disease with a motor performance test series. J Neural Transm Park Dis Dement Sect. 1992;4(2):131-141. 

Przuntek H, Welzel D, Blumner E, et al. Bromocriptine lessens the incidence of mortality in L-dopa-treated parkinsonian patients: prado-study discontinued. Eur J Clin Pharmacol. 1992;43(4):357-363. 

Rabey JM, Nissipeanu P, Korczyn AD. Efficacy of memantine, an NMDA receptor antagonist, in the treatment of Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1992;4:277-282. 

Rabey JM, Vered Y, Shabtai H, Graff E, Korczyn AD. Improvement of parkinsonian features correlate with high plasma levodopa values after broad bean (Vicia faba) consumption. J Neurol Neurosurg Psychiatry. Aug 1992;55(8):725-727. 

Ransmayr G, Kunig G, Gerstenbrand F. Modern therapy of Parkinson's disease. J Neural Transm Suppl. 1992;38:129-140. 

Riederer P, Dirr A, Goetz M, Sofic E, Jellinger K, Youdim MB. Distribution of iron in different brain regions and subcellular compartments in Parkinson's disease. Ann Neurol. 1992;32 Suppl:S101-104. 

Riederer P, Lange KW. Pathogenesis of Parkinson's disease. Curr Opin Neurol Neurosurg. Jun 1992;5(3):295-300. 

Riederer P, Lange KW, Kornhuber J, Danielczyk W. Glutamatergic-dopaminergic balance in the brain. Its importance in motor disorders and schizophrenia. Arzneimittelforschung. Feb 1992;42(2A):265-268. 

Sofic E, Lange KW, Jellinger K, Riederer P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett. Aug 17 1992;142(2):128-130. 

van Laar T, Jansen EN, Essink AW, Neef C. Intranasal apomorphine in parkinsonian on-off fluctuations. Arch Neurol. May 1992;49(5):482-484. 

Van Laar T, Jansen EN, Essink AW, Rutten WJ, Neef C. Rectal apomorphine: a new treatment modality in Parkinson's disease. J Neurol Neurosurg Psychiatry. Aug 1992;55(8):737-738. 

van Laar T, Kruyswijk MR, Jansen EN. [Nasolabial allergic reaction to intranasal administration of apomorphine in Parkinson disease]. Ned Tijdschr Geneeskd. Apr 4 1992;136(14):702-704. 

Wenning GK, Quinn NP, Daniel SE. How accurate is death certification of multiple system atrophy? Lancet. Dec 12 1992;340(8833):1481-1482.

1991

Auff E, Doppelbauer A, Fertl E. Essential tremor: functional disability vs. subjective impairment. J Neural Transm Suppl. 1991;33:105-110. 

Ben-Shachar D, Riederer P, Youdim MB. Iron-melanin interaction and lipid peroxidation: implications for Parkinson's disease. J Neurochem. Nov 1991;57(5):1609-1614. 

Brucke T, Podreka I, Angelberger P, et al. Dopamine D2 receptor imaging with SPECT: studies in different neuropsychiatric disorders. J Cereb Blood Flow Metab. Mar 1991;11(2):220-228. 

Di Trapani G, Stampatore P, La Cara A, Azzoni A, Vaccario ML. Treatment of progressive supranuclear palsy with methysergide. A clinical study. Ital J Neurol Sci. Apr 1991;12(2):157-161. 

Fertl E, Auff E, Doppelbauer A, Waldhauser F. Circadian secretion pattern of melatonin in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1991;3(1):41-47. 

Gerlach M, Riederer P, Przuntek H, Youdim MB. MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease. Eur J Pharmacol. Dec 12 1991;208(4):273-286. 

Jellinger K, Braak H, Braak E, Fischer P. Alzheimer lesions in the entorhinal region and isocortex in Parkinson's and Alzheimer's diseases. Ann N Y Acad Sci. 1991;640:203-209. 

Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol. Jun 1991;14(3):153-197. 

Karamat E, Ilmberger J, Poewe W, Gerstenbrand F. Memory dysfunction in Parkinson patients: an analysis of verbal learning processes. J Neural Transm Suppl. 1991;33:93-97. 

Lestienne P, Nelson I, Riederer P, Reichmann H, Jellinger K. Mitochondrial DNA in postmortem brain from patients with Parkinson's disease. J Neurochem. May 1991;56(5):1819. 

Marschall I, Dal-Bianco P, Maly J, et al. Clinical comparison of dementia in Parkinson's and Alzheimer's disease. J Neural Transm Suppl. 1991;33:81-92. 

Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol. Nov 1991;50(6):743-755. 

Poewe W, Berger W, Benke T, Schelosky L. High-speed memory scanning in Parkinson's disease: adverse effects of levodopa. Ann Neurol. Jun 1991;29(6):670-673. 

Poewe W, Schelosky L, Kleedorfer B. Failure of oral administration of single rising doses of bromocriptine to produce acute anti-Parkinsonian effects. J Neurol Neurosurg Psychiatry. Feb 1991;54(2):186-187. 

Rabey JM, Grynberg E, Graff E. Changes of muscarinic cholinergic binding by lymphocytes in Parkinson's disease with and without dementia. Ann Neurol. Dec 1991;30(6):847-850. 

Rabey JM, Schwartz M, Graff E, Harsat A, Vered Y. The influence of bromocriptine on the pharmacokinetics of levodopa in Parkinson's disease. Clin Neuropharmacol. Dec 1991;14(6):514-522. 

Riederer P, Lange KW, Kornhuber J, Danielczyk W. Pharmacotoxic psychosis after memantine in Parkinson's disease. Lancet. Oct 19 1991;338(8773):1022-1023. 

Russ H, Mihatsch W, Gerlach M, Riederer P, Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: implications for Parkinson's disease? Neurosci Lett. Feb 11 1991;123(1):115-118. 

Schelosky L, Benke T, Poewe WH. Effects of treatment with trihexyphenidyl on cognitive function in early Parkinson's disease. J Neural Transm Suppl. 1991;33:125-132. 

Sofic E, Paulus W, Jellinger K, Riederer P, Youdim MB. Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem. Mar 1991;56(3):978-982. 

Sofic E, Riederer P, Gsell W, Gavranovic M, Schmidtke A, Jellinger K. Biogenic amines and metabolites in spinal cord of patients with Parkinson's disease and amyotrophic lateral sclerosis. J Neural Transm Park Dis Dement Sect. 1991;3(2):133-142. 

Sofic E, Riederer P, Wesemann W, et al. A study of brain dopamine sulfate levels in relation to free dopamine and homovanillic acid in Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1991;3(4):265-271. 

Vaamonde J, Luquin MR, Obeso JA. Subcutaneous lisuride infusion in Parkinson's disease. Response to chronic administration in 34 patients. Brain. Feb 1991;114 ( Pt 1B):601-617.

Youdim MB, Ben-Shachar D, Riederer P. Iron in brain function and dysfunction with emphasis on Parkinson's disease. Eur Neurol. 1991;31 Suppl 1:34-40.

1990

Eberhardt R, Birbamer G, Gerstenbrand F, Rainer E, Traegner H. Citicoline in the treatment of Parkinson's disease. Clin Ther. Nov-Dec 1990;12(6):489-495. 

Fischer P, Gatterer G, Simanyi M, et al. Memory deficits in advanced Parkinson's disease. J Neural Transm Park Dis Dement Sect. 1990;2(1):59-70. 

Gotz ME, Freyberger A, Riederer P. Oxidative stress: a role in the pathogenesis of Parkinson's disease. J Neural Transm Suppl. 1990;29:241-249. 

Jansen EN, van Laar T. ['New wine in old bottles'; therapy for Parkinson disease using subcutaneous apomorphine]. Ned Tijdschr Geneeskd. May 5 1990;134(18):889-891. 

Jellinger K. New developments in the pathology of Parkinson's disease. Adv Neurol. 1990;53:1-16. 

Jellinger K. Neuropathological substrate of dementia in Parkinson's disease. Ann Neurol. Nov 1990;28(5):723-724. 

Jellinger K, Paulus W, Grundke-Iqbal I, Riederer P, Youdim MB. Brain iron and ferritin in Parkinson's and Alzheimer's diseases. J Neural Transm Park Dis Dement Sect. 1990;2(4):327-340. 

Kienzl E, Eichinger K, Sofic E, et al. Urinary dopamine sulfate: regulations and significance in neurological disorders. J Neural Transm Suppl. 1990;32:471-479. 

Lang AE, Riley DE, Vachon L, Lataste X. CQA 206-291 in Parkinson's disease: an acute single escalating dosage study. Can J Neurol Sci. Nov 1990;17(4):416-419. 

Lera G, Vaamonde J, Muruzabal J, Obeso JA. Cabergoline: a long-acting dopamine agonist in Parkinson's disease. Ann Neurol. Oct 1990;28(4):593-594. 

Lestienne P, Nelson J, Riederer P, Jellinger K, Reichmann H. Normal mitochondrial genome in brain from patients with Parkinson's disease and complex I defect. J Neurochem. Nov 1990;55(5):1810-1812. 

Pearce RK, Seeman P, Jellinger K, Tourtellotte WW. Dopamine uptake sites and dopamine receptors in Parkinson's disease and schizophrenia. Eur Neurol. 1990;30 Suppl 1:9-14. 

Poewe W, Benke T, Karamat E, Schelosky L, Wagner M, Sperk G. CSF somatostatin-like immunoreactivity in dementia of Parkinson's disease. J Neurol Neurosurg Psychiatry. Dec 1990;53(12):1105-1106. 

Poewe W, Karamat E, Kemmler GW, Gerstenbrand F. The premorbid personality of patients with Parkinson's disease: a comparative study with healthy controls and patients with essential tremor. Adv Neurol. 1990;53:339-342. 

Poewe W, Luef G, Kleedorfer B, Emre M. Antiparkinsonian activity of a non-ergot dopamine agonist, CV 205-502, in patients with fluctuating Parkinson's disease. Mov Disord. 1990;5(3):257-259. 

Rabey JM, Grynberg E, Graff E. Cholinergic muscarinic binding of blood lymphocytes in patients with Parkinson's disease. Adv Neurol. 1990;53:129-134. 

Rabey JM, Oberman Z, Scharf M, Isakov M, Bar M, Graff E. Bromocriptine blood levels after the concomitant administration of levodopa, amantadine and biperiden in Parkinson's disease. Acta Neurol Scand. May 1990;81(5):411-415.

Rabey JM, Scharf M, Oberman Z, Zohar M, Graff E. Cortisol, ACTH, and beta-endorphin after dexamethasone administration in Parkinson's dementia. Biol Psychiatry. Mar 15 1990;27(6):581-591. 

Rabey JM, Streifler M, Treves T, Korczyn AD. The beneficial effect of chronic lisuride administration compared with levodopa in Parkinson's disease. Adv Neurol. 1990;53:451-455. 

Ransmayr G, Bitschnau W, Schmidhuber-Eiler B, et al. Slowing of high-speed memory scanning in Parkinson's disease is related to the severity of parkinsonian motor symptoms. J Neural Transm Park Dis Dement Sect. 1990;2(4):265-275. 

Rascol O, Fabre N, Teravainen H, et al. CQA 206-291: a novel dopamine agonist in the treatment of Parkinson's disease. Clin Neuropharmacol. Aug 1990;13(4):303-311. 

Rausch WD, Schallauer E, Chan WW, Riederer P, Weiser M. Effects of L-deprenyl and amantadine in an MPTP-model of parkinsonism. J Neural Transm Suppl. 1990;32:269-275. 

Riederer P, Konradi C, Youdim MB. The role of MAO in dopaminergic transmission. Adv Neurol. 1990;53:149-153. 

Speedie L, Rabins P, Pearlson G, Moberg P. Confrontation naming deficit in dementia of depression. J Neuropsychiatry Clin Neurosci. Winter 1990;2(1):59-63. 

Vaamonde J, Luquin MR, Obeso JA. Dopaminergic responsiveness to apomorphine after chronic treatment with subcutaneous lisuride infusion in Parkinson's disease. Mov Disord. 1990;5(3):260-262. 

Youdim MB, Ben-Shachar D, Riederer P. The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease. J Neural Transm Suppl. 1990;32:239-248. 

Youdim MB, Ben-Shachar D, Yehuda S, Riederer P. The role of iron in the basal ganglion. Adv Neurol. 1990;53:155-162.

1989

Birkmayer W, Birkmayer GJ, Vrecko K, Mlekusch W, Paletta B, Ott E. The coenzyme nicotinamide adenine dinucleotide (NADH) improves the disability of parkinsonian patients. J Neural Transm Park Dis Dement Sect. 1989;1(4):297-302. 

Destee A, Martin JJ, Muller JP, et al. [Mitochondrial myopathy. Encephalopathy with lactic acidosis and cerebral infarction]. Rev Neurol (Paris). 1989;145(1):37-48. 

Iriarte LM, Chacon J, Madrazo J, Chaparro P, Vadillo J. Blink reflex in dyskinetic and nondyskinetic patients with Parkinson's disease. Eur Neurol. 1989;29(2):67-70. 

Jellinger K. Trauma as an etiologic agent in Parkinson disease. Mov Disord. 1989;4(1):90-92. 

Jellinger K. Alzheimer pathology in Parkinson's disease. Neurology. Jun 1989;39(6):874-875. 

Luquin MR, Obeso JA, Vaamonde J, Martinez Lage JM. [Orally administered lisuride in the treatment of complex fluctuations of motion in Parkinson disease]. Neurologia. Sep 1989;4(7):229-232. 

Luquin MR, Vaamonde J, Obeso JA. Levodopa and 3-O-methyldopa plasma levels in parkinsonian patients with stable and fluctuating motor response. Clin Neuropharmacol. Feb 1989;12(1):46-54. 

Netherton SD, Elias JW, Albrecht NN, Acosta C, Hutton JT, Albrecht JW. Changes in the performance of parkinsonian patients and normal aged on the Benton Visual Retention Test. Exp Aging Res. Spring-Summer 1989;15(1-2):13-18. 

Obeso JA, Grandas F, Vaamonde J, et al. Motor complications associated with chronic levodopa therapy in Parkinson's disease. Neurology. Nov 1989;39(11 Suppl 2):11-19. 

Obeso JA, Luquin MR, Vaamonde J, Herrero T, Guridi J, Martinez-Lage JM. [Cerebral implants in Parkinson's disease]. Neurologia. Oct 1989;4(8):302-303. 

Obeso JA, Vaamonde J, Grandas F, et al. Overcoming pharmacokinetic problems in the treatment of Parkinson's disease. Mov Disord. 1989;4 Suppl 1:S70-85. 

Poewe W, Kleedorfer B, Gerstenbrand F. [Therapeutic experiences with a slow-release preparation of L-dopa (Madopar "HBS") in patients with advanced Parkinson disease]. Nervenarzt. May 1989;60(5):294-298. 

Poewe W, Kleedorfer B, Wagner M, Benke T, Gasser T, Oertel W. Side-effects of subcutaneous apomorphine in Parkinson's disease. Lancet. May 13 1989;1(8646):1084-1085. 

Rabey JM, Oberman Z, Scharf M, Isakov A, Bar M, Graff E. The influence of levodopa in the pharmacokinetics of bromocriptine in Parkinson's disease. Clin Neuropharmacol. Oct 1989;12(5):440-447. 

Riederer P, Konradi C, Hebenstreit G. [Neurochemical perspectives of the function of monoamine oxidases]. Psychiatr Prax. Aug 1989;16 Suppl 1:7-10. 

Riederer P, Konradi C, Hebenstreit G, Youdim MB. Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol Scand Suppl. 1989;126:41-45. 

Riederer P, Sofic E, Rausch WD, et al. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem. Feb 1989;52(2):515-520. 

Starkstein SE, Rabins PV, Berthier ML, Cohen BJ, Folstein MF, Robinson RG. Dementia of depression among patients with neurological disorders and functional depression. J Neuropsychiatry Clin Neurosci. Summer 1989;1(3):263-268. 

Vaamonde J, Luquin MR, Obeso JA. Levodopa consumption reduces dopaminergic receptor responsiveness in Parkinson's disease. Clin Neuropharmacol. Aug 1989;12(4):271-284. 

Youdim MB, Ben-Shachar D, Riederer P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol Scand Suppl. 1989;126:47-54. 

Zimmers T, Ma F. Cases in electrocardiography. Am J Emerg Med. Jul 1989;7(4):434-436.

1988

Brucke T, Bankiewicz K, Harvey-White J, Kopin I. The partial dopamine receptor agonist terguride in the MPTP-induced hemiparkinsonian monkey model. Eur J Pharmacol. Apr 13 1988;148(3):445-448. 

Danielczyk W, Streifler M, Konradi C, Riederer P, Moll G. Platelet MAO-B activity and the psychopathology of Parkinson's disease, senile dementia and multi-infarct dementia. Acta Psychiatr Scand. Dec 1988;78(6):730-736. 

Iriarte LM, Chacon J, Madrazo J, Chaparro P, Vadillo J. Blink reflex in 57 parkinsonian patients with correlation between the clinical and electrophysiological parameters. Funct Neurol. Apr-Jun 1988;3(2):147-156. 

Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry. Apr 1988;51(4):540-543. 

Mier JW, Vachino G, van der Meer JW, et al. Induction of circulating tumor necrosis factor (TNF alpha) as the mechanism for the febrile response to interleukin-2 (IL-2) in cancer patients. J Clin Immunol. Nov 1988;8(6):426-436. 

Mogi M, Harada M, Kiuchi K, et al. Homospecific activity (activity per enzyme protein) of tyrosine hydroxylase increases in parkinsonian brain. J Neural Transm. 1988;72(1):77-82. 

Obeso JA, Grandas F, Vaamonde J, Luquin MR, Martinez-Lage JM. Continuous dopaminergic stimulation for Parkinson's disease: facts and fancy. Funct Neurol. Oct-Dec 1988;3(4):413-427. 

Obeso JA, Luquin MR, Grandas F, Vaamonde J, Martinez Lage JM. Levodopa therapy and motor fluctuations in Parkinson's disease. Ann Neurol. Nov 1988;24(5):696-697. 

Obeso JA, Luquin MR, Vaamonde J, Martinez Lage JM. Subcutaneous administration of lisuride in the treatment of complex motor fluctuations in Parkinson's disease. J Neural Transm Suppl. 1988;27:17-25. 

Poewe W, Kleedorfer B, Gerstenbrand F, Oertel W. Subcutaneous apomorphine in Parkinson's disease. Lancet. Apr 23 1988;1(8591):943. 

Poewe WH, Lees AJ, Stern GM. Dystonia in Parkinson's disease: clinical and pharmacological features. Ann Neurol. Jan 1988;23(1):73-78. 

Rausch WD, Hirata Y, Nagatsu T, Riederer P, Jellinger K. Tyrosine hydroxylase activity in caudate nucleus from Parkinson's disease: effects of iron and phosphorylating agents. J Neurochem. Jan 1988;50(1):202-208. 

Riederer P. Factors contributing to fluctuations of the dopaminergic nigro-striatal feedback system in Parkinson's disease. J Neural Transm Suppl. 1988;27:191-199. 

Riederer P, Rausch WD, Schmidt B, et al. Biochemical fundamentals of Parkinson's disease. Mt Sinai J Med. Jan 1988;55(1):21-28. 

Riederer P, Sofic E, Heuschneider G, Benedetti MS, Dostert P. Secondary (toxic) parkinsonism as model of Parkinson's disease. Funct Neurol. Oct-Dec 1988;3(4):449-457. 

Sofic E, Riederer P, Heinsen H, et al. Increased iron (III) and total iron content in post mortem substantia nigra of parkinsonian brain. J Neural Transm. 1988;74(3):199-205.

1987

Alberca R, Rafel E, Chinchon I, Vadillo J, Navarro A. Late onset parkinsonian syndrome in Hallervorden-Spatz disease. J Neurol Neurosurg Psychiatry. Dec 1987;50(12):1665-1668. 

Birbamer G, Ransmayr G, Gerstenbrand F, Poewe W. Therapeutic experiences with an abeorphine derivative in Parkinson's disease. Adv Neurol. 1987;45:591-592. 

Brucke T, Danielczyk W, Simanyi M, Sofic E, Riederer P. Terguride: partial dopamine agonist in the treatment of Parkinson's disease. Adv Neurol. 1987;45:573-576. 

Cash R, Dennis T, L'Heureux R, Raisman R, Javoy-Agid F, Scatton B. Parkinson's disease and dementia: norepinephrine and dopamine in locus ceruleus. Neurology. Jan 1987;37(1):42-46. 

Gerstenbrand F, Poewe W. Dopaminergic-peptidergic interactions in extrapyramidal disorders: a review of the clinical evidence. Adv Neurol. 1987;45:67-73. 

Jellinger K. Neuropathological substrates of Alzheimer's disease and Parkinson's disease. J Neural Transm Suppl. 1987;24:109-129. 

Jellinger K. Overview of morphological changes in Parkinson's disease. Adv Neurol. 1987;45:1-18. 

Jellinger K. [Lisuride in the combination treatment of Parkinson disease]. Wien Med Wochenschr. Apr 30 1987;137(7-8):155-159. 

Jellinger K. Quantitative changes in some subcortical nuclei in aging, Alzheimer's disease and Parkinson's disease. Neurobiol Aging. Nov-Dec 1987;8(6):556-561. 

Jellinger K, Bliesath H. Adjuvant treatment of Parksinson's disease with budipine: a double-blind trial versus placebo. J Neurol. Jun 1987;234(5):280-282. 

Korczyn AD, Inzelberg R, Treves T, Neufeld M, Reider I, Rabey PM. Dementia of Parkinson's disease. Adv Neurol. 1987;45:399-403. 

Kucharski LT, Wagner RL, Friedman JH. An investigation of the coexistence of abnormal involuntary movements, parkinsonism, and akathisia in chronic psychiatric inpatients. Psychopharmacol Bull. 1987;23(1):215-217. 

Obeso JA, Grandas F, Vaamonde J, Rosario Luguin M, Martinez-Lage JM. Apomorphine infusion for motor fluctuations in Parkinson's disease. Lancet. Jun 13 1987;1(8546):1376-1377. 

Obeso JA, Luquin MR, Vaamonde J, Grandas F, Martinez Lage JM. Continuous dopaminergic stimulation in Parkinson's disease. Can J Neurol Sci. Aug 1987;14(3 Suppl):488-492. 

Obeso JA, Luquin MR, Vaamonde J, et al. [Continuous dopaminergic stimulation in Parkinson disease]. Neurologia. Sep-Oct 1987;2(5):227-234. 

Poewe W, Gerstenbrand F, Ransmayr G. Experience with selegiline in the treatment of Parkinson's disease. J Neural Transm Suppl. 1987;25:131-135. 

Poewe W, Lees AJ, Steiger D, Stern GM. Foot dystonia in Parkinson's disease: clinical phenomenology and neuropharmacology. Adv Neurol. 1987;45:357-360. 

Poewe WH, Lees AJ. The pharmacology of foot dystonia in parkinsonism. Clin Neuropharmacol. 1987;10(1):47-56. 

Poewe WH, Lees AJ, Stern GM. Clinical and pharmacokinetic observations with Madopar HBS in hospitalized patients with Parkinson's disease and motor fluctuations. Eur Neurol. 1987;27 Suppl 1:93-97. 

Rabey JM, Treves T, Streifler M, Korczyn AD. Comparison of efficacy of lisuride hydrogen maleate with increased doses of levodopa in parkinsonian patients. Adv Neurol. 1987;45:569-572. 

Ransmayr G, Poewe W, Ploerer S, Birbamer G, Gerstenbrand F. Psychometric findings in clinical subtypes of Parkinson's disease. Adv Neurol. 1987;45:409-411. 

Ransmayr G, Schmidhuber-Eiler B, Karamat E, Engler-Plorer S, Poewe W, Leidlmair K. Visuoperception and visuospatial and visuorotational performance in Parkinson's disease. J Neurol. Dec 1987;235(2):99-101. 

Reed D, Labarthe D, Chen KM, Stallones R. A cohort study of amyotrophic lateral sclerosis and parkinsonism-dementia on Guam and Rota. Am J Epidemiol. Jan 1987;125(1):92-100. 

Riederer P, Konradi C, Schay V, et al. Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl. Adv Neurol. 1987;45:111-118. 

Riederer P, Kruzik P. Biochemical and morphological changes in the aging brain. Electroencephalogr Clin Neurophysiol Suppl. 1987;39:389-395.

Rinne UK, Rinne JO, Rinne JK, Laakso K. Chemical neurotransmission in the parkinsonian brain. Med Biol. 1987;65(2-3):75-81. 

Rutgers AW, Lakke JP, Paans AM, Vaalburg W, Korf J. Tracing of dopamine receptors in hemiparkinsonism with positron emission tomography (PET). J Neurol Sci. Sep 1987;80(2-3):237-248. 

Seeman P, Bzowej NH, Guan HC, et al. Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology. Dec 1987;1(1):5-15.

1986

Birkmayer W, Riederer P. Biological aspects of depression in Parkinson's disease. Psychopathology. 1986;19 Suppl 2:58-61. 

Brucke T, Riederer P. [Neurobiologic and pharmacologic studies on the pathogenesis of Parkinson disease]. Wien Med Wochenschr. Aug 31 1986;136(15-16):401-408. 

Gerstenbrand F, Ransmayr G. Nosography of Parkinson's disease. J Neural Transm Suppl. 1986;22:119-128. 

Goldenberg G, Wimmer A, Auff E, Schnaberth G. Impairment of motor planning in patients with Parkinson's disease: evidence from ideomotor apraxia testing. J Neurol Neurosurg Psychiatry. Nov 1986;49(11):1266-1272. 

Guttman M, Seeman P, Reynolds GP, Riederer P, Jellinger K, Tourtellotte WW. Dopamine D2 receptor density remains constant in treated Parkinson's disease. Ann Neurol. May 1986;19(5):487-492. 

Jolkkonen J, Soininen H, Halonen T, et al. Somatostatin-like immunoreactivity in the cerebrospinal fluid of patients with Parkinson's disease and its relation to dementia. J Neurol Neurosurg Psychiatry. Dec 1986;49(12):1374-1377. 

Poewe W, Gerstenbrand F. [Clinical subtypes of Parkinson disease]. Wien Med Wochenschr. Aug 31 1986;136(15-16):384-387. 

Poewe WH, Lees AJ, Stern GM. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin Neuropharmacol. 1986;9(5):430-439. 

Poewe WH, Lees AJ, Stern GM. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology. Nov 1986;36(11):1528-1530. 

Ransmayr G, Poewe W, Plorer S, Gerstenbrand F, Leidlmair K, Mayr U. Prognostic implications of the motor symptoms of Parkinson's disease with respect to clinical, computertomographic and psychometric parameters. J Neural Transm. 1986;67(1-2):1-14. 

Riederer P, Youdim MB. Monoamine oxidase activity and monoamine metabolism in brains of parkinsonian patients treated with l-deprenyl. J Neurochem. May 1986;46(5):1359-1365. 

Scatton B, Dennis T, L'Heureux R, Monfort JC, Duyckaerts C, Javoy-Agid F. Degeneration of noradrenergic and serotonergic but not dopaminergic neurones in the lumbar spinal cord of parkinsonian patients. Brain Res. Aug 13 1986;380(1):181-185. 

Schnaberth G. ["Parkinson plus." Multisystem involvement in Parkinson disease]. Fortschr Med. Mar 13 1986;104(10):205-212. 

Schnaberth G. [Depression and Parkinson syndrome]. Wien Med Wochenschr. Aug 31 1986;136(15-16):391-393.

1958-1985

1985

Birkmayer W, Knoll J, Riederer P, Youdim MB, Hars V, Marton J. Increased life expectancy resulting from addition of L-deprenyl to Madopar treatment in Parkinson's disease: a longterm study. J Neural Transm. 1985;64(2):113-127.

Jorgensen OS, Riederer P. Increased synaptic markers in hippocampus of depressed patients. J Neural Transm. 1985;64(1):55-66.

Rinne JO, Rinne JK, Laakso K, Lonnberg P, Rinne UK. Dopamine D-1 receptors in the parkinsonian brain. Brain Res. Dec 16 1985;359(1-2):306-310.
 

1984

Birkmayer W, Riederer P. Deprenyl prolongs the therapeutic efficacy of combined L-DOPA in Parkinson's disease. Adv Neurol. 1984;40:475-481.

Jellinger K, Riederer P. Dementia in Parkinson's disease and (pre) senile dementia of Alzheimer type: morphological aspects and changes in the intracerebral MAO activity. Adv Neurol. 1984;40:199-210.

Liano H, Lopez-Lozano JJ, Ramirez A, Rabes C, Pascual ML. [Use of bromocriptine in Parkinson diseases in low doses at a slow rate. 40 patients]. Arch Neurobiol (Madr). May-Jun 1984;47(3):143-150.

Rinne UK, Rinne JO, Rinne JK, Laakso K, Lonnberg P. Brain neurotransmitters and neuropeptides in Parkinson's disease. Acta Physiol Pharmacol Latinoam. 1984;34(3):287-299.

1983

Birkmayer W, Birkmayer G, Lechner H, Riederer P. DL-3,4-threo-DOPS in Parkinson's disease: effects on orthostatic hypotension and dizziness. J Neural Transm. 1983;58(3-4):305-313.

Birkmayer W, Danielczyk W, Riederer P. Symptoms and side effects in the course of Parkinson's disease. J Neural Transm Suppl. 1983;19:185-199.

Birkmayer W, Knoll J, Riederer P, Youdim MB. (-)-Deprenyl leads to prolongation of L-dopa efficacy in Parkinson's disease. Mod Probl Pharmacopsychiatry. 1983;19:170-176.

Gerstenbrand F, Ransmayr G, Poewe W. Deprenyl (selegiline) in combination treatment of Parkinson's disease. Acta Neurol Scand Suppl. 1983;95:123-126.

Grundig E, Mayer W, Gerstenbrand F. [Biosynthesis of amino acids from glucose in the central nervous system in the Parkinson syndrome]. Arch Psychiatr Nervenkr. 1983;233(5):397-408.

Poewe W, Gerstenbrand F, Ransmayr G, Plorer S. Premorbid personality of Parkinson patients. J Neural Transm Suppl. 1983;19:215-224.

Riederer P, Jellinger K. Neurochemical insights into monoamine oxidase inhibitors, with special reference to deprenyl (selegiline). Acta Neurol Scand Suppl. 1983;95:43-55.

Riederer P, Jellinger K, Danielczyk W, et al. Combination treatment with selective monoamine oxidase inhibitors and dopaminergic agonists in Parkinson's disease: biochemical and clinical observations. Adv Neurol. 1983;37:159-176.

Riederer P, Reynolds GP, Jellinger K, Seemann D, Danielczyk W. Tranylcypromine isomers in Parkinson's disease. Effect of low doses on monoamine oxidase inhibition and blood pressure response. Mod Probl Pharmacopsychiatry. 1983;19:154-161.

Rinne UK, Rinne JK, Rinne JO, et al. Brain enkephalin receptors in Parkinson's disease. J Neural Transm Suppl. 1983;19:163-171.

Rinne UK, Rinne JO, Rinne JK, Laakso K, Laihinen A, Lonnberg P. Brain receptor changes in Parkinson's disease in relation to the disease process and treatment. J Neural Transm Suppl. 1983;18:279-286.

Streifler M, Rabey MJ. Long-term effects of L-deprenyl in chronic levodopa treated parkinsonian patients. J Neural Transm Suppl. 1983;19:265-272.
 

1982

Birkmayer W, Riederer P, Youdim MB. (-)Deprenyl in the treatment of Parkinson's disease. Clin Neuropharmacol. 1982;5(2):195-230.

Gerstenbrand F, Klingler D, Pfeiffer B. [Essential tremor: phenomenology and epidemiology (author's transl)]. Nervenarzt. Jan 1982;53(1):46-53.

Jellinger K. Adjuvant treatment of Parkinson's disease with dopamine agonists: open trial with bromocriptine and CU 32-085. J Neurol. 1982;227(2):75-88.

Jellinger K, Grisold W. Cerebral atrophy in Parkinson syndrome. Exp Brain Res. 1982;Suppl 5:26-35.

Jorgensen OS, Reynolds GP, Riederer P, Jellinger K. Parkinson's disease putamen: normal concentration of synaptic membrane marker antigens. J Neural Transm. 1982;54(3-4):171-179.

Rabins PV. Psychopathology of Parkinson's disease. Compr Psychiatry. Sep-Oct 1982;23(5):421-429.

Riederer P, Jellinger K. Morphological and biochemical changes in the aging brain: pathophysiological and possible therapeutic consequences. Exp Brain Res. 1982;Suppl 5:158-166.

Tune LE, Folstein M, Rabins P, Jayaram G, McHugh P. Familial manic-depressive illness and familial Parkinson's disease: a case report. Johns Hopkins Med J. Aug 1982;151(2):65-70.

1981

Kienzl E, Riederer P, Jellinger K, Wesemann W. Transitional states of central serotonin receptors in Parkinson's disease. J Neural Transm. 1981;51(1-2):113-122.

Konig MP. [Bromocriptine therapy]. Schweiz Med Wochenschr. Feb 28 1981;111(9):303-308.

Rabey JM, Vardi Y, Ravid R, Ayalon D. Dissociation of thyrotropin and prolactin responsiveness to thyrotropin releasing hormone stimulation in L-dopa treated parkinsonian patients. Horm Res. 1981;15(2):78-87.

Reynolds GP, Riederer P. Tranylcypromine isomers in the treatment of Parkinson's disease. Biochemical effects. Int Pharmacopsychiatry. 1981;16(1):30-33.

Reynolds GP, Riederer P, Sandler M. Tranylcypromine isomers and Parkinson's disease: new aspects of an old drug. J R Soc Med. Sep 1981;74(9):649-652.

1980

Danielczyk W, Riederer P, Seemann D. Benign and malignant types of Parkinson's disease: clinical and patho-physiological characterization. J Neural Transm Suppl. 1980(16):199-210.

Grundig E, Gerstenbrand F. [Comparison between the effects of L-dopa, prodipine and amantadine on the serum and CSF amino acid levels in Parkinson's disease (author's transl)]. Wien Klin Wochenschr. Dec 19 1980;92(24):868-871.

Jellinger K, Riederer P, Tomonaga M. Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl. 1980(16):111-128.

Lechner H, Bertha G, Ott E. [Current treatment of Parkinsonian syndrome]. Med Welt. Oct 1980;31(40):1444-1446.

Riederer P. L-dopa competes with tyrosine and tryptophan for human brain uptake. Nutr Metab. 1980;24(6):417-423.

Streifler M, Avrami E, Rabey JM. L-dopa and the secretion of sebum in Parkinsonian patients. Eur Neurol. 1980;19(1):43-48.

Wuketich S, Riederer P, Jellinger K, Ambrozi L. Quantitative dissection of human brain areas: relevance to transmitter analyses. J Neural Transm Suppl. 1980(16):53-67.

1970 - 1979

 Birkmayer W, Riederer P, Youdim BH. Distinction between benign and malignant type of Parkinson's disease. Clin Neurol Neurosurg. 1979;81(3):158-164.

Podiwinsky F, Mentasti M, Riederer P, Birkmayer W. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)]. Wien Klin Wochenschr. May 11 1979;91(10):332-337.

Reynolds GP, Riederer P, Sandler M. 2-Phenylethylamine and amphetamine in human brain: effects of L-deprenyl in Parkinson's disease [proceedings]. Biochem Soc Trans. Feb 1979;7(1):143-145.

Reynolds GP, Riederer P, Sandler M, Jellinger K, Seemann D. Amphetamine and 2-phenylethylamine in post-mortem Parkinsonian brain after (-)deprenyl administration. J Neural Transm. 1978;43(3-4):271-277.

Riederer P, Rausch WD, Birkmayer W, Jellinger K, Danielczyk W. Dopamine-sensitive adenylate cyclase activity in the caudate nucleus and adrenal medulla in Parkinson's disease and in liver cirrhosis. J Neural Transm Suppl. 1978(14):153-161.

Riederer P, Rausch WD, Birkmayer W, Jellinger K, Seemann D. CNS Modulation of adrenal tyrosine hydroxylase in Parkinson's disease and metabolic encephalopathies. J Neural Transm Suppl. 1978(14):121-131.

Riederer P, Youdim MB, Birkmayer W, Jellinger K. Monoamine oxidase activity during (--)-deprenil therapy: human brain post-mortem studies. Adv Biochem Psychopharmacol. 1978;19:377-382.

Birkmayer W, Riederer P, Ambrozi L, Youdim MB. Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study. Lancet. Feb 26 1977;1(8009):439-443.

Gerstenbrand F. 2. The symptomatology of the apallic syndrome. Monogr Gesamtgeb Psychiatr Psychiatry Ser. 1977;14:14-21.

Riederer P, Birkmayer W, Seemann D, Wuketich S. Brain-noradrenaline and 3-methoxy-4-hydroxyphenylglycol in Parkinson's syndrome. J Neural Transm. 1977;41(4):241-251.

Ambrozi L, Birkmayer W, Riederer P, Youdim MB. L-dopa and (-)-deprenil in the treatment of Parkinson's disease: a long-term study [proceedings]. Br J Pharmacol. Nov 1976;58(3):423P-424P.

Binder H, Gerstenbrand F, Grunberger J, Grundig E, Schubert H. [Experience with a l-dopa retard preparation in the peroral long-term therapy of the Parkinsonian syndrome]. Nervenarzt. Nov 1976;47(11):656-660.

Riederer P, Wuketich S. Time course of nigrostriatal degeneration in parkinson's disease. A detailed study of influential factors in human brain amine analysis. J Neural Transm. 1976;38(3-4):277-301.

Birkmayer W, Danielczyk W, Neumayer E, Riederer P. Dopaminergic supersensitivity in parkinsonism. Adv Neurol. 1975;9:121-129.

Birkmayer W, Riederer P. Responsibility of extrastriatal areas for the appearance of psychotic symptoms (clinical and biochemical human post-mortem findings). J Neural Transm. 1975;37(2):175-182.

Birkmayer W, Riederer P, Youdim MB, Linauer W. The potentiation of the anti akinetic effect after L-dopa treatment by an inhibitor of MAO-B, Deprenil. J Neural Transm. 1975;36(3-4):303-326.

Gerstenbrand F, Binder H. [Parkinson's syndrome; epidemiology, clinical aspects and therapy]. Dtsch Krankenpflegez. Nov 1975;28(11):598-604.

Gerstenbrand F, Binder H, Kozma C, Pusch ST, Reisner T. [Infusion therapy with mif (melanocyte inhibiting factor) in Parkinson's disease (author's transl)]. Wien Klin Wochenschr. Dec 26 1975;87(24):822-823.

Weiss J, Grundig E, Gerstenbrand F. [The activity of aminotransferases in serum and cerebrospinal fluid in neurological diseases (author's transl)]. Wien Klin Wochenschr. Dec 12 1975;87(23):799-803.

Birkmayer W, Danielczyk W, Neumayer E, Riederer P. Nucleus ruber and L-dopa psychosis: biochemical post-mortem findings. J Neural Transm. 1974;35(2):93-116.

Birkmayer W, Linauer W, Mentasti M, Riederer P. [2-year experiences with a combination treatment of Parkinsonism with L-dopa and a decarboxylase inhibitor (Benserazid, Ro 4-4602)]. Wien Med Wochenschr. Jun 1 1974;124(22):340-344.

Ambrozi L, Birkmayer W, Danielczyk W, Neumayer E, Riederer P. [Biochemical aspects of human behavior]. Wien Z Nervenheilkd Grenzgeb. 1973;31(3):191-215.

Ambrozi L, Birkmayer W, Danielczyk W, Neumayer E, Riederer P. [Biochemical aspects of human behaviour (author's transl)]. Folia Clin Int (Barc). Sep 1973;23(9):565-587.

Bernheimer H, Birkmayer W, Hornykiewicz O, Jellinger K, Seitelberger F. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. Dec 1973;20(4):415-455.

Birkmayer W, Danielcyk W, Neumayer E, Riederer P. L-dopa level in plasma, primary condition for the kinetic effect. J Neural Transm. 1973;34(2):133-143.

Gerstenbrand F, Grunberger J, Schubert H. [Quantitative testing methods for objectification of the effect of prolonged L-dopa therapy in parkinsonism]. Nervenarzt. Aug 1973;44(8):428-433.

Geser CA, Muller-Hess R, Dufresne JJ, Felber JP, Vannotti A. [Effect of L-dopa on pituitary hormones and on carbohydrate and fat metabolism in normal persons and in patients with Parkinsonism]. Schweiz Med Wochenschr. May 12 1973;103(19):690-697.

Jellinger K. [Morphology and biochemistry of Parkinson's syndrome]. Cesk Patol. Feb 1973;9(1):1-13.

Birkmayer W, Danielczyk W, Neumayer E, Riederer P. The balance of biogenic amines as condition for normal behaviour. J Neural Transm. 1972;33(2):163-178.

Gerstenbrand F, Grundig E, Musiol A. [Current treatment of Parkinsonism with amantadine hydrochloride]. Pol Tyg Lek. Jul 3 1972;27(23):878-879.

Grundig E, Gerstenbrand F, Oberhummer J, Simanyi M, Schedl R, Weiss J. [Biochemical aspects of the effect of L-dopa in patients with Parkinson's disease]. Z Neurol. 1972;203(1):73-90.

Jellinger K, Neumayer E. Unusual late-onset type of hallervorden-Spatz disease. Clinico-pathological study of a case presenting as parkinsonism. Z Neurol. 1972;203(2):105-118.

Rinne UK, Riekkinen PJ, Laaksonen H, Sonninen VJ. Acetylcholinesterase activity of different brain areas in Parkinson's disease. Acta Neurol Scand Suppl. 1972;51:137-138.

Gerstenbrand F, Grunberger J, Oberhummer I. [Results of treatment with amantadine hydrochloride in Parkinson's syndrome using psychological test study methods. (Preliminary report)]. Wien Med Wochenschr. May 8 1971;121(19):390-397.

Jellinger K, Jirasek A. Neuroaxonal dystrophy in man: character and natural history. Acta Neuropathol (Berl). 1971;5:Suppl 5:3-16.

Gerstenbrand F, Grunberger J, Oberhummer I. [Results of treatment with amantadine hydrochloride in Parkinson's syndrome using psychological test study methods. (Preliminary report)]. Hno. Nov 1970;18(11):390-397.

Grundig E, Gerstenbrand F. [Correlation between Parkinsonism symptoms and a disorder in the amino acid metabolism in CNS]. Wien Klin Wochenschr. Nov 6 1970;82(45):811-816.

1958 - 1969

Avenarius HJ, Gerstenbrand F. [Experiences with ethybenzatropine (Ponalid) in the treatment of Parkinson's syndrome]. Wien Klin Wochenschr. Sep 5 1969;81(36):622-625 passim.

Grundig E, Gerstenbrand F, Bruck J, Gnad H, Prosenz P, Simanyi M. [The effect of the administration of amino acids, especially of L-dopa and alpha-methyldopa, on the composition of cerebrospinal fluid in extrapyramidal syndromes. II. Alterations of cerebrospinal fluid in patients with Parkinson's disease and chorea following the administration of alpha-methyldopa]. Dtsch Z Nervenheilkd. 1969;196(3):256-265.

Avenarius HJ, Gerstenbrand F. [Kr 339, a new tremor-inhibiting preparation for the therapy of Parkinson's syndrome]. Wien Klin Wochenschr. Jun 7 1968;80(23):460-462.

Jellinger K. [Neuroaxonal dystrophies]. Verh Dtsch Ges Pathol. 1968;52:92-126.

Jellinger K. [Progressive pallidal atrophy]. J Neurol Sci. Jan-Feb 1968;6(1):19-44.

Jellinger K. [Prolonged post-traumatic encephalopathy]. Wien Med Wochenschr. Sep 21 1968;118(38):747-753.

Jellinger K, Danielczyk W. ["Striato-nigral degeneration"]. Acta Neuropathol (Berl). Apr 8 1968;10(3):242-257.

Bartholini G, Burkard WP, Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature. Aug 19 1967;215(5103):852-853.

Birkmayer W, Mentasti M. [Further experimental studies on the catecholamine metabolism in extrapyramidal diseases (Parkinson and chorea syndromes)]. Arch Psychiatr Nervenkr. Aug 8 1967;210(1):29-35.

Bruck J, Gerstenbrand F. [Functional decerebration presenting the picture of an apallic syndrome due to high dosage majeptil therapy. A contribution to the question of the mode of action and site of attack of certain neuroleptics]. Nervenarzt. Oct 1967;38(10):459-464.

Bruck H, Gerstenbrand F, Gnad H, Grundig E, Prosenz P. [Comparative biochemical studies in organic parkinsonian syndromes and drug induced parkinsonian syndromes]. Psychiatr Neurol (Basel). 1966;151(2):81-87.

Gerstenbrand F, Prosenz P. [On the treatment of Parkinson's syndrome with monoamine oxidase inhibitors alone and in combination with L-dopa]. Praxis. Nov 18 1965;54(46):1373-1377.

Avenarius HJ, Gerstenbrand F, Riechert T. [Studies on the Effect of Stereotaxic Operations in the Parkinson Syndrome.]. Wien Klin Wochenschr. Oct 9 1964;76:689-696.

Avenarius HJ, Gerstenbrand F. [Benztropine (Cogentin) in Drug Therapy of the Parkinson Syndrome.]. Wien Klin Wochenschr. Dec 27 1963;75:924-926.

Gerstenbrand F, Hoff H, Prosenz P. [Therapeutic experiences with Lucidril in neuropsychiatric disease pictures.]. Wien Med Wochenschr. Jun 29 1963;113:539-543.

Birkmayer W, Hornykiewicz O. [The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia.]. Wien Klin Wochenschr. Nov 10 1961;73:787-788.

Ehringer H, Hornykiewicz O. [Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system.]. Klin Wochenschr. Dec 15 1960;38:1236-1239.

Gerstenbrand F, Pateisky K. [Clinical & electromyographic experiences with 10870 (aturban) in the treatment of Parkinson's syndrome.]. Wien Klin Wochenschr. Dec 5 1958;70(49):978-980.

Gerstenbrand F, Tschabitscher H. [Experiences with the anti-parkinsonian drug akineton.]. Wien Klin Wochenschr. Apr 11 1958;70(15):261-264.